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I 
 
Abstract 
 
The present work aimed to the discovery of new anticancer agents and to the 
total synthesis of a natural compound with selectivity towards cancer hypoxia. 
In this context, a first project involved the design and synthesis of N-
acylhydrazone based inhibitors of lactate dehydrogenase A (LDH-A). The 
structures of the new molecules where designed by means of virtual screening 
techniques and synthesized to obtain a library of analogs which were evaluated 
on the isolated enzyme. Active compounds were also screened on cell cultures 
of non-Hodgkins lymphoma and one of them proved to be a promising inhibitor, 
suggesting that the N-acylhydrazone could be a suitable scaffold in the field of 
LDH-A inhibitors. 
The second project aimed to the synthesis of Galloflavin (GF) analogs and to 
the study of the compound’s SAR. GF is an LDH-A inhibitor which was 
previously identified and synthesized by our group. Its poor solubility and 
stability prevented us from studying its SAR maintaining the core structure. 
Therefore, the synthesis of three potential classes of structural analogs was 
devised and carried out. One compound was found to reproduce GF’s 
behaviour on the enzyme and in cell, therefore being a good starting point for 
the study. A small library of analogs was synthesized and biological tests are 
ongoing to acquire in-depth knowledge about the key pharmacophores of this 
interesting inhibitor. 
The third project was carried out at Aarhus University in the Chemical Biology 
group lead by Prof. Thomas B. Poulsen. The work focused on the total 
synthesis of Rakicidin A, a complex macrolide of natural origin which was 
identified and isolated two decades ago from soil samples and since then is 
known for its interesting properties in selectively inducing cell death in hypoxic 
environments and being also active on cancer stem cells. The total synthesis 
involved several steps including key enantioselective reactions to build the 5 
stereocenters on the molecule. The project was carried out in collaboration with 
other components of the group and was successfully completed in early 2015. 
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Abbreviations and acronyms 
 
β-HOAsn: β-hydroxyasparagine 
β-HOAsp: β-hydroxyaspartic acid 
ALT1: Alanine transaminase 1  
APD: (E)-4-amido-2,4-pentadienoate 
BCR-ABL: Breakpoint cluster region – Abelson 
BSA: Bovine serum albumin 
CAM: Cerium ammonium molybdate 
CaMKII γ: Calcium/calmodulin-dependent protein kinase type II gamma 
CML: Chronic myelogenous leukemia 
CSCs: Cancer stem cells 
DCM: Dichloromethane 
DCC: N,N'-Dicyclohexylcarbodiimide 
DCU: Dicyclohexylurea 
DIBAL: Diisobutylaluminum hydride 
DMAP: Dimethylaminopyridine 
DME: 1,2-Dimethoxyethane 
DMF: N,N-dimethylformamide 
DMP: Dess–Martin periodinane 
DMSO: Dimethyl sulfoxide 
DNA: Deoxyribonucleic acid 
DSC: N,N′-disuccinimidyl carbonate 
EA: Ellagic acid 
EDCI: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
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EGFR: Epidermal growth factor receptor 
EMT: Epithelial to mesenchymal transition 
FCC: Flash column chromatography 
GA: Gallic acid 
GF: Galloflavin 
HDAC: Histone deacetylase 
HER2: Human epidermal growth factor receptor 2 
HIF: Hypoxia-inducible factor 
HPLC: High performance liquid chromatography 
HWE: Horner-Wadsworth-Emmons 
LDH: Lactate dehydrogenase 
LiHMDS: Lithium bis(trimethylsilyl)amide 
MET: Mesenchymal to epithelial transition 
mTOR: Mammalian target of rapamycin 
NAD+: Nicotinamide adenine dinucleotide (oxidized form) 
NADH: Nicotinamide adenine dinucleotide (reduced form) 
NADP+: Nicotinamide adenine dinucleotide phosphate (oxidized form) 
NADPH: Nicotinamide adenine dinucleotide phosphate (reduced form) 
NBS: N-bromosuccinimide 
NCI: National cancer institute 
NMR: Nuclear magnetic resonance 
NOE: Nuclear Overhauser effect 
PCC: Pyridinium chlorochromate 
PDH: Pyruvate dehydrogenase  
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PDK: Pyruvate dehydrogenase kinase 
PG: Protecting group 
Ph: Philadelphia chromosome 
pO2: Partial oxygen pressure 
PyBOP: (benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate) 
RakA: Rakicidin A 
RakB: Rakicidin B 
RNA: Ribonucleic acid 
SAR: Structure-activity relationship 
SCs: Stem cells 
THF: Tetrahydrofuran 
TLC: Thin layer chromatography 
TMEDA: Tetramethylethylenediamine 
TOP1: Topoisomerase I 
TOP2: Topoisomerase II 
TyrK: Tyrosine kinase 
UM6: Urolithin M6 
VEGF: Vascular endothelial growth factor 
VS: Virtual Screening 
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Figure 1 Survival rates by type, US, 2004-2010, for some of the most common human cancers 
CHAPTER 1 
 
Modern anti-cancer therapy: tools and strategies 
 
 
Cancer is currently the cause of almost 20% of deaths that occur every year in 
high-income countries1.  
During the past several decades more than 100 different types of cancer were 
identified2 and nowadays we face a highly heterogeneous situation in terms of 
prognosis and patient conditions, depending on the type and subtype of 
neoplasm encountered. As shown in figure 1, the five-year relative survival rate 
in the US in the interval 2004-2010 varied from a dreadful 7% in pancreas 
cancer to an encouraging 99% in prostate cancer, with some of the other most 
common types covering the whole range in between3. 
The reasons behind this divergence are complex, and include the genetic and 
epigenetic abnormalities that characterize differently each cancer type, causing 
specific downstream pathways that can in some case be exploited for 
therapeutic purposes4, as well as incidence and acquired resistance to chemo- 
and radiotherapy, which can also vary considerably and are obviously to be 
taken into account.  
 
 
 
 
 
 
 
 
 
This scenario might suggest that researchers and physicians should hardly be 
able to address cancer as a single disease, but it is nevertheless possible - to 
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some extent - to describe some crucial common features of cancer biology that 
can contribute to set order in the vast complexity of cancer diagnosis and 
treatment.  
At the beginning of the XXI century, Hanahan and Weinberg established six key 
features common to almost all types of cancer - since then defined as The 
Hallmarks of Cancer2 - giving the scientific community some very precious tools 
towards a better understanding of the neoplastic disease. 
These hallmarks are: sustaining proliferative signaling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, and activating invasion and metastasis. 
The hallmarks of cancer outline a common profile of the neoplastic cell that can 
be identified as an immortal cell with aggressive invasive power which is able to 
create a local environment favorable to its own survival and, at the metastasis 
state, can create colonies of spawned cells that attack distal tissues in different 
organs. 
However, despite this concept might suggest a view of cancer tissue as a 
homogeneous malignant mass, recent advancements show that plasticity and 
heterogeneity are in fact key features of tumors, and they need to be taken into 
account in the quest for new treatments (see paragraph 1.3). 
The therapeutic challenge is therefore remarkable, and it is nowadays clear that 
a targeted therapy hitting specific molecular features that characterize different 
cancer types is the most promising strategy, and most importantly the less 
harmful for the patient4, since the principles on which classic chemotherapies 
were based can no more be considered sustainable, due to their dose-limiting 
toxicities and their sometimes life-threatening side effects. 
In the next paragraphs, a selection of the most common classic and modern 
approved therapies5 will be described together with their mechanisms of action, 
as well as some recent cutting edge concepts inspiring new paths for the drug 
discovery of anticancer compounds.  
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1.1 An overview of classic and modern therapies 
Drugs approved for clinical use in cancer treatment can be divided in two main 
areas: “classic” cytotoxic chemotherapy and targeted therapy6. Cytotoxic 
chemotherapy is the traditional therapy based on compounds that interact with 
some fundamental processes of cell cycle, therefore impairing the proliferation 
of cancer and often inducing programmed cell death7. These compounds attack 
non-selectively all types of cells, including healthy ones, and their efficacy is 
mostly based on the fact that cancer cells divide with a much higher rate than 
normal cells, making them more sensitive to compounds that arrest cell cycle 
since at any time a higher portion of cancer cells are undergoing cell division. 
The dose is chosen in an interval where the ratio of cancer cell death vs normal 
cell death is optimal7. Side effects are obviously severe and they have always 
constituted a major issue in cancer treatment since the life of the patient can 
sometimes be seriously threatened by these compounds. 
Targeted therapy is the modern approach to chemotherapy and it involves the 
use of compounds that selectively target specific molecular abnormalities 
occurring in certain types of cancer, therefore reducing considerably the risk of 
side effects since effective targeted therapies are meant to only attack cancer 
cells8. Of course this also reduces the range of applicability of the compound 
and requires an intense study of the genetic variability of the different types of 
cancer that can lead to peculiar processes which can be targeted to kill the 
malignant cell.  
 
1.1.1 Cytotoxic therapy 
The commonly used cytotoxic chemotherapics approved for clinic exploit 
several different mechanisms of action. They can be divided into: alkylating 
agents, DNA crosslinkers, inhibitors of dihydrofolate reductase, nucleoside 
analogs, antimicrotubular agents, DNA intercalators, topoisomerase inhibitors 
and proteasome inhibitors6. Other less common compounds have different 
mechanisms which will not be treated in this section. 
Alkylating agents are among the very first compounds to be used as anticancer 
drugs. They are mostly represented by the class of nitrogen mustards, 
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electrophilic compounds which alkylate guanine bases on the N-7 position, 
causing permanent DNA damage which in turn causes p53 induced apoptosis9. 
Cyclophosphamide is a famous member of this class, and it acts as a prodrug 
requiring activation of the oxazaphosphorine ring by P450 enzymes to achieve 
the active form in vivo10. The toxicity of cyclophosphamide is however quite 
concerning, especially due to the fact that its first metabolite is the reactive 
aldehyde acrolein, which is responsible for urotoxicity, neurotoxicity, and 
nephrotoxicity11. 
DNA crosslinkers such as cisplatin, carboplatin and oxaliplatin act through a 
similar mechanism, binding to guanine after displacement of a ligand (chloride 
in cisplatin) by a water molecule, making the platinum center more reactive12. 
The same process takes place after the first bond is formed, generating a cross-
link between two strands of DNA, leading to programmed cell-death initiated by 
proteins of the caspase family. 
Inhibitors of dihydrofolate reductase interfere with the enzyme responsible of 
the reduction of dihydrofolate to tetrahydrofolate, which is a key process in the 
synthesis of thymine, a necessary nucleotide in DNA synthesis13. A famous 
antifolate drug is methotrexate, a compound which binds competitively to the 
binding site of natural folates with a 1000-fold higher affinity therefore blocking 
the enzymatic activity and inducing cell death14. Methotrexate is also used in the 
therapy against rheumatoid arthritis, where it acts with a different mechanism 
based on a multitarget pattern which is still not completely disclosed15. 
Nucleoside analogs are compounds that reproduce the structure of natural 
nucleosides, which can be used as building blocks by the cell to synthesise 
DNA. Minimal structural differences on a key site of the nucleoside lead the 
DNA strand to be unusable, eventually causing apoptosis16. Gemcitabine is a 
difluorinated analog of deoxycytidine which replaces cytidine in RNA during 
DNA replication, it is a common compound in cytotoxic chemotherapy and it has 
also shown to be active in the inhibition of ribonucleotide reductase, a process 
which deprives the cell of the necessary supply of deoxyribonucleotides17. 
Antimicrotubular agents are compounds that interact with the dynamic of 
microtubules having the effect of inducing apoptosis. Microtubules are crucial 
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polymeric structures found in the cell, which are involved in several basic 
functions, including the formation of mitotic spindles during chromosome 
separation prior to cell division18. They are non-covalent polymers of a dimer of 
alpha and beta tubulin, two isoforms of a class of structural globular proteins19. 
They are continuously engaged in non-equilibrium dynamics and they are 
characterized by a so called “dynamic instability”, meaning that their size vary 
constantly during the life cycle of a cell with periods of shortening, growth and 
paused states20. This dynamicity must be maintained to allow the cell to survive 
and undergo mitosis, and for this reason it represents an interesting target for 
compounds aiming at cytotoxicity. The two main classes of approved 
antimicrotubular agents are Vinca alkaloids and Taxanes. The former, including 
vincristine and vinblastine, are compounds extracted from the leaves of 
Catharanthus roseus (Vinca rosea) and discovered in the 60's as potent 
antitumor agents21; the latter, including paclitaxel and docetaxel, are alkaloids of 
Taxus brevifolia and Taxus baccata, and were identified less than a decade 
later than Vinca alkaloids21. These two classes of compounds bind tubulin in 
two very distinct sites, defined as the Vinca binding domain and the Taxane 
binding domain, and they were previously thought to act with two opposite 
mechanisms. It is clear in fact that Vinca alkaloids stimulate in vitro 
depolymerization of microtubules whereas Taxanes stabilize them22. 
Nevertheless it has been demonstrated that at low, clinically relevant 
concentration, Vinca alkaloids don’t destroy microtubules while still inducing 
apoptosis23. As a consequence it is now widely accepted that both these 
classes of molecules effectively interfere with cell mitosis by simply blocking 
microtubule dynamics20, therefore acting with similar mechanisms despite the 
different binding sites. 
DNA intercalators are planar aromatic molecules, often constituted by polycyclic 
structures, which show high affinity with DNA nitrogen bases and bind to DNA 
double helixes by occupying the space between two nucleosides24. The 
presence of the intercalator disrupts the optimal DNA geometry and interrupts 
replication. Doxorubicin and daunorubicin, both commonly used chemoterapics, 
are intercalators but also showed a range of additional mechanisms such as 
topoisomerase II binding and free radical generation25.   
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Topoisomerase inhibitors interact with the crucial topoisomerase I (TOP1) and 
topoisomerase II (TOP2) enzymes blocking their function of supercoiled DNA 
unwinding agents which they carry out after transcription and replication26. 
These enzymes are ubiquitous in mammalians and they are essential for cell 
survival. Studies on TOP1 knockout mice showed that their absence causes 
death during embryogenesis27. The inhibitors exert their action with the 
stabilization of the covalent DNA cleavage complexes, therefore increasing their 
steady-state concentration and causing accumulation of broken DNA strands, 
leading to apoptosis28. Common TOP1 inhibitors are topotecan and irinotecan, 
both synthetic analogs of natural compound camptothecin, whereas among the 
TOP2 inhibitors we can find etoposide and teniposide, semisynthetic glycosides 
of podophyllotoxin, an antimicotic extracted from Podophyllum peltatum (a.k.a. 
mayapple or American mandrake)29. 
Proteasome inhibitors are molecules that act through complex mechanisms, 
interrupting the proteolytic action of the proteasome protein complexes30. In 
cancer cells these complexes can destroy crucial tumor suppressors as p53, 
therefore their inhibition can restore the normal function of pro-apoptotic factors 
and induce cell death. The first approved proteasome inhibitor was bortezomib, 
a boronic acid modified dipeptide31, and in 2012 a new compound (carfilzomib) 
was approved for the treatment of multiple myeloma32. 
 
1.1.2 Targeted therapy 
Modern cancer treatment is rapidly expanding from the old cytotoxic based 
therapies to more appropriate and focused targeted compounds. Advanced 
molecular and chemical biology unveiled a number of aberrant molecular 
pathways in cancer that have been exploited in the last few decades to obtain 
potent drugs with high specificity and relatively lower toxicity. The focus in this 
paragraph will be on tyrosine-kinase (TyrK) inhibitors, vascular endothelial 
growth factor (VEGF) pathway inhibitors, epidermal growth factor receptor 
(EGFR) inhibitors and mammalian target of rapamycin (mTOR) inhibitors. 
TyrK inhibitors were the first compounds to open the era of targeted therapy, 
with the milestone discovery of imatinib. This drug exploits the aberration of the 
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Philadelphia chromosome (Ph)33, a genetic mutation in chronic myelogenous 
leukemia (CML) which generates the fusion protein BCR-ABL, a constitutively 
active tyrosine kinase which can be found in all CML patients34. BCR-ABL itself 
was found to be both sufficient and necessary to cause CML, therefore 
representing an exceptionally appealing target for the treatment of this 
neoplasm35–37. Since then imatinib has also been approved for the treatments of 
other forms of cancer such as gastrointestinal stromal tumor and Ph-positive 
acute lymphoblastic leukemia. The use of imatinib has more recently 
encountered some issues arisen by the insurgence of mutation-induced 
resistance38 and to the inability of the molecule to attack cancer stem cells 
therefore leading to a risk of relapse after an apparent complete remission has 
been achieved (see paragraph 1.4). 
VEGF pathway inhibitors interact with a molecular mechanism involved in the 
creation and sustainment of one of the hallmarks of cancer: angiogenesis. 
VEGF is a pro-angiogenic growth factor responsible for the vascularization of 
cancer cells and induced by hypoxic cells in need of increased blood supply39. 
Bevacizumab is a recombinant humanized monoclonal antibody that prevents 
the binding of VEGF to VEGF receptors therefore blocking its growth-
stimulating effect40. Despite the initial great hope behind this drug it has now 
been recognized that its effect might be in reality less striking than expected 
and nowadays bevacizumab is mostly used in combination with classic 
chemotherapy41, especially for the treatment of advanced colorectal cancer42. 
Its action is thought to be exerted through a “normalization” of blood vessels, 
which facilitates the action of cytotoxic drugs by letting them further inside 
neoplastic tissue, rather than a real block of blood supply and angiogenesis43. 
EGFR inhibitors interfere with cell membrane receptors which are upregulated 
in some cancers and stimulate cell proliferation. HER2 is a specific type of 
EGFR, encoded by a gene which is known to be overexpressed in 20-30% of 
breast cancers44 and it’s connected with severe disease and poor prognosis. 
Trastuzumab is a monoclonal antibody EGFR inhibitor which binds to the HER2 
receptor inducing cell cycle arrest during the G1 phase while furthermore 
activating tumor suppressor p2745. 
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mTOR inhibitors are compounds interacting with a serine/threonine protein 
kinase involved in several growth and proliferation signals46 which was first 
identified while investigating the mechanism of action of rapamycin47, a natural 
macrolide produced by Streptomyces hygroscopicus48 with known 
immunosuppressant action and mainly used to prevent rejection in organ 
transplantation. Temsirolimus is a synthetic analog of rapamycin and is 
approved for the treatment of advanced renal-cell carcinoma49. 
1.2 An emerging hallmark: cancer cells reprogramming energy 
metabolism  
In a later re-edition of their famous paper, Hanahan and Weinberg introduced 
the idea of a new generation of “emerging hallmarks”, that arise from the 
knowledge acquired thanks to the research carried out in the first decade of the 
2000’s50. These emerging hallmarks were identified to be reprogramming 
energy metabolism and evading immune destruction. Flanking these newly 
identified capabilities, two “enabling characteristics” were described, as 
conditions facilitating the acquisition of both core and emerging hallmarks: 
genome instability and tumor-promoting inflammation.  
We will here focus on the abnormal metabolic phenotype which can be 
recognized in the majority of cancer types, is particularly appealing in a 
therapeutic perspective and represents the core rationale of our research on 
lactate dehydrogenase inhibitors. This unexpected feature was first discovered 
in the first half of the XX century by Otto Warburg, who initially believed it to be 
one, if not the most important, cause of cancer51. Genetic alterations and 
cellular response to the neoplastic microenvironment (such as hypoxia in some 
cases) contribute to induce a crucial switch in the way tumors carry out their 
energetic metabolism and produce ATP: quiescent normal cells metabolize 
pyruvate after glycolysis mainly through the oxygen-dependent cooperation of 
Krebs cycle and oxidative phosphorylation, carried out in mitochondria, 
oxidizing nutrients to CO2 and storing energy in a highly efficient manner52; on 
the contrary, cancer cells reprogram their metabolic pathway towards the so 
called aerobic glycolysis: regardless of the oxygen level, the cell relies largely 
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Figure 2 Diagram of the pathways involved in the Warburg effect (bold arrows are upregulated 
processes) 
on glycolysis for energy production, deviating most of the produced pyruvate to 
the synthesis of lactate through lactate dehydrogenase (LDH), neglecting the 
function of mitochondria and gaining oxygen independence53 (the Warburg 
effect, see figure2). 
This switch seems counterintuitive, and there is still uncertainty regarding the 
reason why tumors privilege anaerobic glycolysis for energy production. In fact, 
this reprogrammed metabolism is ≈18-fold less efficient than oxidative 
phosphorylation, in terms of molecules of ATP produced per molecule of 
glucose consumed50. 
 
In response to this lack of efficiency, and in the presence of a pressing energy 
requirement to carry out fast division and invasion, cancer cells show a 
characteristic upregulation of glucose transporters54, making the increase of 
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glucose uptake a fundamental signature which has often been used for 
diagnostic purposes. Furthermore, aerobic glycolysis is always shown to be 
associated with activated oncogenes55 and mutated tumor suppressors. In 
hypoxic conditions, the increase of the glycolytic pathway is even more 
relevant56, due to the mediation of hypoxia-inducible factor 1 (HIF-1) which 
activates transcription of genes encoding glucose transporters and glycolytic 
enzymes (including LDH). 
Because of its unexpectedness, there is still debate around which advantage 
cancer cells might gain from this metabolic switch. It was initially postulated by 
Warburg that this mechanism is a consequence of a decrease in ATP 
production by potentially damaged mitochondria57. This hypothesis has lost 
credibility in time, since it has been shown that in most tumors mitochondria are 
actually active and well-functioning, consuming oxygen at normal rates58 and 
sometimes play a key role in tumor development59. 
Alternative explanations are based on the facts that tumors develop with a fast 
pace and lack sufficient oxygen supply in some areas, especially in the first 
stages. Despite its low efficiency, anaerobic glycolysis is a much faster process 
than oxidative phosphorylation and most importantly it is an oxygen 
independent process; this features might account for a strategic switch to a 
metabolic phenotype that better suits the mutated needs of cancer cells60. 
Despite these partially satisfactory explanations, the most valued hypothesis so 
far is a revival of an old paper that was recently revisited and given credit61. It is 
based on the knowledge that an increase of glycolysis allows for the production 
of a high amount of glycolytic intermediates, suitable for use as building blocks 
in various synthetic pathways62. Rapidly dividing cells need a fast supply of 
nutrients and simple molecules to assemble new daughter cells, therefore an 
inefficient energetic metabolism with a high output in terms of building blocks 
might be preferable. Moreover, anaerobic glycolysis might be an effective way 
of maintaining a proper redox homeostasis in the cell, since it supplies the key 
compounds involved in the pentose phosphate pathway, which in turn is a 
valuable source of NADPH, an important cofactor providing reducing power to a 
large number of biosynthetic ways63. 
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The established relationship between tumor cells and the Warburg phenotype 
opened the path towards a number of valuable new targets for anticancer 
therapy. Several enzymes are involved in glycolysis and some of them have 
been recognized as potentially druggable with the aim of developing a new 
family of compounds often referred to as glycolytic inhibitors64. Among the most 
interesting targets over which drug development research is ongoing it is 
possible to find enzymes such as hexokinase, phosphofructokinase, 
glyceraldehyde-3-phosphate dehydrogenase, pyruvate kinase and lactate 
dehydrogenase64. Part of the innovative research reported in this work is about 
the design, synthesis and evaluation of new inhibitors of lactate dehydrogenase 
(see chapters 2 and 3), based on the evidence that inhibition of such enzyme 
can block tumor progression and, in some cases, induce programmed cell 
death65. 
 
1.3 Cancer hypoxia and cancer stem cells 
Neoplastic tissues are highly heterogeneous63. This intrinsic characteristic 
common to the vast majority of solid tumors is a consequence of several factors 
related to the malignant phenotype with two of the most therapeutically relevant 
ones being the proven existence of regions of hypoxia and the presence of local 
aggregates of the so called cancer stem cells (CSCs). 
Hypoxic tissues are characterized by a partial oxygen pressure (pO2) which falls 
in a significantly lower range than healthy tissue. Depending on the topic 
(diagnosis, chemotherapy resistance, radiotherapy resistance), hypoxia can be 
defined with slightly different pO2 values but it is normally accepted that a tissue 
with a pO2 lower than 10 mmHg is considered hypoxic (healthy tissues have 
average pO2 values ranging from 40 to 50 mmHg)66. 
The most common tumor types have median pO2 between 5 and 15 mmHg66, 
with peak areas reaching levels between 0 and 5 mmHg therefore being close 
to complete anoxia67. 
The constantly low oxygen pressure in tumors is a result of the imbalance 
between the O2 fast consumption and its inadequate supply, that is caused from 
fast replication and insufficient or chaotic vascularization68. Two kinds of 
hypoxia have been postulated: diffusion-limited (or chronic) hypoxia and 
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Figure 3 Diffusion-limited hypoxia in tumor angiogenesis. 
perfusion-limited (or acute) hypoxia. Diffusion-limited hypoxia, discovered in the 
50’s, is a consequence of vascularization not keeping pace with the fast 
expanding tumor and forming tissue portions outside the range of influence of 
local vessels69. In these conditions a gradient of pO2 is formed and it is 
estimated that at a distance higher than 100 µm a chronic hypoxic environment 
is established70 (figure 3).  
 
 
 
 
 
 
 
 
 
 
 
Perfusion-limited hypoxia arises from the leaky and structural abnormal tumor 
vasculature which can locally induce temporary closure or reduced flow with a 
consequent transient hypoxia generated in the proximity of the involved 
vessels71,72. Regional tumor oxygenation can vary intensively in short periods of 
time with acute hypoxia being restored to normoxia often within a few hours63. 
The two types of hypoxia have different biological consequences and 
therapeutic implications. Chronic hypoxia, characterized by a pO2 gradient, can 
often generate similar diffusion-induced gradients in the concentration of drugs 
delivered from the blood stream73, causing peripheral hypoxic cells to be 
exposed to only a negligible concentration of the active compound. Acute 
hypoxia, leading to a non-distance-dependent decrease of pO2, is accompanied 
by a higher risk of metastasis due to the presence of hypoxic cells in direct 
contact with blood vessels74 and therefore more likely to enter the circulation. 
Hypoxic cells have a selective survival advantage over the normoxic ones, due 
to the contribution of at least three distinguished mechanisms: hypoxia-
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mediated selection, inducing mutation of tumor suppressor proteins and 
promoting the insurgence of aggressive phenotypes75; genomic instability, 
which suppresses DNA repair pathways therefore selecting and promoting cells 
with mutations76; changes in oxygen-sensitive pathways, which promote 
changes in metabolism, angiogenesis and cell survival mechanisms77. 
As a consequence of all the factors described above, hypoxia plays a key role 
in resistance to chemo- and radiotherapy78 (an oxygen-dependent process), it 
leads tissues to have an increased potential for invasive growth and metastasis 
and it is always connected with aggressive tumors and  poor prognosis79. 
The second factor contributing to the heterogeneous phenotype of cancer is the 
presence of cancer stem cells (CSCs) and their role in the life cycle of a tumor. 
It has been demonstrated that tumor tissue is characterized by hierarchically 
organized populations, recreating the common structure that can be found in 
normal tissue80, with the presence of stem cells (SCs), progenitor cells and fully 
differentiated cells. Classically, stem cells are defined as populations of cells 
with three main abilities: self-renewal, creation of multiple lineages and 
extensive proliferation81. CSCs are a type of cells that can be found in most 
tumors in relatively small amounts, which show a set of properties which is 
parallel to normal SCs and have therefore been associated with them under 
many points of view. They are indeed characterized by a strong tumor-initiating 
potential, they are immortal and self-renewing and they can spawn a progeny of 
differentiated cells82. It is now commonly accepted to refer to these peculiar 
subpopulations as stem cells even though it must be clear that it is a term that 
arises from the parallel abilities that can be identified between normal stem cells 
and CSCs and it doesn’t intend to equate their biological properties and 
significance82. 
There is uncertainty on whether CSCs arise from normal SCs after mutation or 
through a “backwards” reacquisition of self-renewal ability by dedifferentiation of 
committed progenitor cells83 and in fact both mechanisms might be relevant. On 
the other hand, a clear connection between epithelial to mesenchymal transition 
(EMT) and CSC formation has been established and it might be the key to 
explain the origin and the role of CSCs in cancer84. 
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Figure 4 Intrinsic and induced formation of cancer stem cells. The induced mechanism might involve 
epithelial to mesenchymal transition. 
EMT is a fundamental physiological process which is normally observed during 
embryonic development and tissue repair. It involves a morphological change in 
epithelial cells with loss of cell-cell junctions and transformation into motile 
mesenchymal cells85. These cells have high invasive potential and can relocate 
distally, later undergoing mesenchymal to epithelial transition (MET) to restore 
their epithelial morphology and differentiate according to the needs of the 
organism. Cells that have undergone EMT show a signature phenotype 
characterized by the presence of canonical markers such as vimentin, N-
cadherin and fibronectin86. These markers have been also identified in CSCs, 
leading to the conclusion that EMT can induce the transformation of non-CSCs 
into CSC-like populations87,88. Once a CSC has acquired motility it has the 
possibility of entering the blood flow (intravasation), relocate and invade new 
tissues after re-exiting the flow (extravasation), all features which are directly 
connected with tumor metastatic potential. 
There might be therefore a double cause to the formation of CSCs, an intrinsic 
presence of an oncogenic population derived from modified stem or progenitor 
cells and an EMT-induced formation of CSCs with metastatic potential82 (figure 
4). 
 
 
 
 
 
 
The presence of CSCs in tumor is therefore correlated with a complex network 
of causes and consequences. As seen above, this peculiar subpopulation of 
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Figure 5 Several scenarios might arise from the formation of CSCs. These cells are thought to be 
involved in primary tumor generation, relapse and metastasis. 
cancer cells has been attributed a role in primary tumor generation89 and 
metastasis90 (figure 5A and 5C) due to its clear tumor-initiating potential. 
Additionally, an increasing body of literature also highlights the possibility that 
CSCs with mesenchymal phenotype might be directly involved with both de 
novo and acquired chemo- and radio-resistance91–93, and moreover be the 
cause of tumor relapse after a first successful treatment94 (figure 5B). 
Resistance and relapse are features that CSCs share with tumor hypoxia and 
interestingly a number of key studies have now elucidated an actual connection 
between low oxygen pressure and the EMT/CSC concept95–98, often through the 
HIF signaling pathway. It becomes then clear that hypoxia itself can not only 
maintain but even contribute to reprogram non-stem cancer cells towards a 
stem-like phenotype, being once again confirmed to be directly involved in both 
metastasis and resistance/relapse, and highlighting the urgent need for new 
hypoxia- and CSC-selective therapies. 
 
 
 
 
 
 
 
 
 
 
Several routes can be followed to select suitable targets for CSC treatment, and 
some promising inhibitors are already undergoing advanced study. Interfering 
with EMT is of course a strategy of relevant priority given its strict connection 
with the formation of CSCs. Among the possible ways of achieving this, one is 
the blockage of EMT-inducing signals, such as reduced oxygen tension, 
cytokines99 or TGFβ receptor kinase100. This approach is though limited by the 
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large variety of EMT-inducing signals93. Alternatively, a promising path to follow 
is targeting the mesenchymal phenotype in CSCs, interfering with proteins like 
vimentin, N-cadherin and fibronectin101,102. Other options are the inhibition of 
EMT-associated transcription factors103 and block of MET104, the latter more 
directly connected with the prevention of metastasis and aimed to lock cells into 
their high motility state preventing them from actually colonizing new tissue and 
proliferate. HDAC inhibitors are interestingly believed to be an additional way of 
counteracting EMT since histone deacetylation is crucial in this process and 
since these compounds can also affect HIF-1 and nuclear factor-kB, inducing 
differentiation of CSCs into normal tumor cells105. 
Other successful approaches might be based on non EMT-related mechanisms. 
Omacetaxine showed to be active in the inhibition of protein synthesis by 
targeting ribosomes and inducing apoptosis of CSCs in tyrosine kinase resistant 
CML106 and berbamine binds to the ATP site of CaMKII γ and by inhibiting its 
phosphorylation triggers apoptosis of leukemia CSCs107. 
HIF is clearly another appealing target due to its strict connection with hypoxic 
environments: a high throughput screening identified new ligands able to bind to 
the PAS-B domain of the HIF-2α subunit and prevent HIF-2 heterodimerization 
and DNA-binding activity, though not affecting HIF-1 fucntion108, whereas a 
cyclic CLLFVY peptide showed opposite selectivity, binding to HIF-1α and 
reducing HIF-1-mediated hypoxia response signaling while showing no 
interaction with HIF-2109. 
The development of promising therapies to fight metastasis and cancer relapse 
due to the presence of CSCs is therefore supported by a large spectrum of 
potential tools that need to be properly explored, in order to find the ideal 
Achilles’ heel (or, potentially, heels) of this reluctant subpopulations of cells. 
 
1.4 Aims of this work 
The totality of my PhD research has been revolving around the chemical 
manipulation of synthetic building blocks in order to obtain biologically active 
molecules able to stop, and to some extent kill, cancer cells. 
  
17 
 
The research on LDH-A inhibitors (see chapters 2 and 3) aimed to identify, 
through means of virtual screening and analog generation, new classes of 
compounds able to interfere with the energy reprogramming that characterizes 
distinctively the neoplastic phenotype. In chapter 2 I will describe the discovery 
of a promising N-acylhydrazone based compound which showed activity on the 
isolated LDH-A enzyme and in cells. Chapter 3 is about the study of a 
previously discovered LDH-A inhibitor (Galloflavin, or GF), specifically focusing 
on the disclosure of its structure-activity relationship (SAR) through the 
development of a structurally analog class of compounds which allowed us to 
explore the function of the key pharmacophores without having to deal with the 
challenging physicochemical properties of the original molecule. 
On chapter 4 I will describe the results of the 6-months period I spent at Aarhus 
University, working in the Chemical Biology lab under the supervision of Prof. 
Thomas B. Poulsen, where I collaborated to the total synthesis of Rakicidin A, a 
macrocyclic depsipeptide of natural origin which exhibits great hypoxia-selective 
activity on cancer cells, and has the ability to also target CSCs. The synthetic 
effort was successfully completed in 2015 thanks to the collaboration of many 
members of the group and ongoing studies are now trying to disclose the 
molecular target of the compound through modern chemical biology tools.  
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CHAPTER 2 
 
Identification of N-acylhydrazone derivatives as novel lactate 
dehydrogenase A inhibitors 
 
 
2.1 Introduction 
Reprogramming of cells energy metabolism is an emerging hallmark of cancer, 
as described in paragraph 1.2. Cancer cells, compared to their healthy 
counterparts, increase the rate of glucose uptake and mainly metabolize it to 
lactate through the so called aerobic glycolysis, as opposed to the more energy-
efficient but oxygen-dependent mitochondrial oxidative phosphorylation 
process. This metabolic shift termed Warburg is independent of in-cell oxygen 
levels, and provides ATP and substrates for cell growth and division. Given the 
dependence of cancer cells on anaerobic glycolysis, this peculiar metabolic 
feature could be exploited for selective anticancer therapies. 
Lactate dehydrogenase constitutes a key enzyme in glycolysis, catalyzing the 
inter-conversion of pyruvate to lactate with simultaneous oxidation of NADH to 
NAD+, which is essential to maintain the glycolytic flow. LDH is a tetrameric 
enzyme built by the assembly of two types of subunits, LDH-A and LDH-B, 
encoded by the highly related genes, ldh-a and ldh-b110,111. 
 
 
 
 
 
 
 
 
 
 
Figure 5 LDH structure. The four assembled subunits, each one containing a NADH molecule, are 
displayed in different colors. 
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Subunits A and B are also known as M (muscle) and H (heart) respectively112, 
from the tissues where they can be commonly found in the body, and show a 
high sequence similarity (~75%)113 in the binding site domains. Five different 
combinations have been observed in the tetramer that forms after the assembly 
of these subunits: the homotetramers 4H and 4M, and the three mixed 
tetramers (3H1M, 2H2M, 1H3M)114. For clarity, 4H homotetramers (therefore 
tetramers of LDH-A subunits) will be from now on referred to as simply LDH-A.  
The relevance of the A isoform of the enzyme as a critical factor in 
tumorigenesis is supported by a consistent amount of data, whereas conflicting 
results have been reported concerning the implications of LDH-B115,116, and its 
function in cancer cells has not yet been fully elucidated. LDH-A expression is 
constantly up-regulated in tumors and it is widely accepted to correlate with 
tumor size and poor prognosis55,117,118. In several tumor models, silencing LDH-
A expression by siRNA or shRNA was found to inhibit cell growth, migration and 
in vivo tumorigenesis119,120. Furthermore, it has been demonstrated that when 
LDH-A expression is silenced in noncancerous cultured cells, proliferation and 
protein synthesis are not impaired121. These appealing traits depict LDH-A 
inhibitors as potentially safe agents, able to impair cancer cell metabolism and 
growth without causing damage to normal tissues. 
Because of these features, the rush to the discovery of new LDH-A inhibitors 
has recently started and the number of research papers published in the field is 
constantly increasing (figure 6). 
 
 
 
 
 
 
 
 
 
Figure 6 Papers published in peer reviewed journals concerning inhibition of LDH, source www.scopus.com 
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Several LDH-A inhibitors have been reported so far including the natural 
product gossypol122, its derivative FX-11 (1)65 and the pyruvate mimetic 
oxamate (2)123. These compounds set the initial trend in terms of molecular 
structure and SAR, and many of the inhibitors developed subsequently (such as 
the N-hydroxyindole 3) are somehow derived or inspired by them. In particular, 
they all share the presence of a carboxylic acid moiety, which is normally 
unusual in drugs for pharmacokinetic reasons, but it appears to be highly 
relevant in the binding with the active site of LDH-A and it is present in almost 
all the most successful inhibitors (sometimes as its bioisostere sulfonamide as 
in 4), with exceptions including galloflavin (see chapter 3), which anyway 
features a high number of hydrogen bond donors in the form of OH groups.  
 
In fact, hydrogen bonds play a key role in the binding between ligands and the 
active site in LDH. Figure 8 depicts a tridimensional rendering of oxamate 
bound to the site, surrounded by the catalytic residues Arg-105, Arg-168, His-
192 and Asp-165 and establishing H-bonds with each one of them. NADH is 
also present and it might as well be involved in interactions with the ligand. 
 
 
 
 
 
 
 
 
 
 
Figure 7 Inhibitors of LDH-A 
Figure 8 Ligand-site interactions between oxamate and LDH-A 
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These interactions are crucial and represent a direct consequence of the 
physiological function of the enzyme, binding the endogenous substrates 
(pyruvate and lactate) and carrying out redox transformations directly involving 
proton transfer and carbonyl activation. It is therefore not surprising that many 
of the inhibitors discovered so far carry key structural features mimicking this 
behavior while binding to the active site. 
A more recent class of LDH-A inhibitors is represented by the the N-
hydroxindole-derivatives124,125 developed by Minutolo and coworkers (e.g. 
compound 3 in figure 7) which have been extensively studied, also in 
combination with classic chemotherapics126 or in conjugation with glucose127. 
Other compounds were developed through either a fragment based approach 
by AstraZeneca128 and Ariad Pharmaceuticals129, or screening by Genentech130 
and GSK131.  
Despite a considerable share of the published molecules are active in the low 
micromolar or high nanomolar range on the isolated enzyme, in many cases the 
authors reported limited cellular activity or not suitable pharmacokinetic 
properties. 
In this context, the identification of new structures showing high inhibitory 
activity both on the isolated enzyme and in the cell, associated with suitable 
physicochemical properties, still represents an open challenge to researchers in 
the field and no definitive answer has been found yet. 
With the intention of entering this quest, our group undertook a first discovery 
campaign that ended in the identification of galloflavin132, a promising inhibitor 
which retains good cellular activity and which has been subsequently also 
studied by competing groups133,134. However, the compound presents several 
practical issues and is unsuitable for direct structural development. This aspect 
is directly addressed in chapter 3, where the development of promising 
galloflavin analogs is described. 
In this chapter I report the discovery of a novel class of LDH-A inhibitors based 
on an entirely new structure, selected through a virtual screening (VS) 
campaign and subsequently investigated through the development of a small 
library of analogs to disclose their structure-activity relationship (SAR). The 
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computational study and biological assays were carried out by collaborators of 
Prof. Maurizio Recanatini and Prof. Giuseppina Di Stefano, who completed the 
discovery team where our group supplied the synthetic contribute. 
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2.2 Results and discussion 
This study aimed to discover new compounds with LDH-A inhibitory potential 
without the structural bias of pre-existing ligands, in order to expand the 
chemical space currently occupied by active scaffolds in the international 
literature. 
The process therefore started through a de novo virtual screening procedure, 
which was carried out with a previously optimized protocol allowing for the 
inclusion of the LDH active site loop flexibility and resulting in three different 
protein conformations135. The ligands were extracted from the Asinex database 
containing around 500000 unique structures, through a filter according to 
physical and chemical descriptors based on a variation of Lipinski‘s rule of five, 
selected to optimize pharmacokinetic properties, preventing poor absorption 
and permeation and excluding poor chemical stability or toxicity. After an 
iterative process of docking and selection, the most representative ligands were 
selected considering their interactions with the catalytic residues, and 67 
promising molecules were chosen for biological tests and purchased in 
minimum quantity to obtain preliminary information. 
The selected compounds were tested on purified human LDH-A and three of 
them (5a-c, figure 9), featuring a common N-acylhydrazone scaffold, were 
found to cause enzyme inhibition at micromolar level.  
 
 
 
 
Figure 10 shows the binding mode of these three compounds as resulted from 
the docking. As before mentioned, they enter the positively charged substrate 
binding pocket through the negative carboxylate. Although 5b is characterized 
by the carboxylic group in the para- position, this moiety is involved in 
electrostatic interactions similarly to 5a and 5c, whereas its aromatic ring 
reaches a deeper cavity where hydrophobic residues (e.g. Ile251 and Leu164) 
Figure 9 Three new N-acylhydrazone based LDH-A inhibitors 
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are located. Similarly, the furan ring of 5a-c occupies the inner lipophilic domain 
corresponding to the nicotinamide and ribose binding site. Finally, the remaining 
portion of the molecules overlaps with the ribose and phosphate NADH domain 
without making interactions with the distal adenine pocket. In particular, the 
hydrazone groups are involved in hydrogen bonds with Ala29, Val30 and Gly96 
and the terminal phenyl ring, nitrile group and pyridine ring of 5a, 5b and 5c 
respectively are located in a solvent exposed pocket. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Once the first promising compounds were identified the workflow proceeded to 
the chemical synthesis step. A synthetic approach was devised to obtain 5a-c in 
a fast and efficient manner, in order to validate the chemical structures obtained 
by the Asinex service. With the synthetic tool in hand we could subsequently 
produce a library of analogs to explore the SAR of this new class of inhibitors. 
Figure 10 binding mode of compounds 5a-c 
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The docking study suggested that the carboxylic moiety engaged interactions 
similar as the ones that the endogenous substrate is involved in and therefore 
that portion was kept unchanged in most variants, while we focused on 
modifications concerning the central heterocycle and the other terminal part. 
The common synthetic strategy to achieve the desired compounds 5a-p was 
designed to bring diversity to the library through a fast and modular assembly of 
building blocks. 
The final scaffold, was built via a two steps process. Step 1 was a Suzuki 
reaction to couple the appropriate bromo-substituted heterocyclic aldehydes 6a-
e (portion B) and the suitable boronic acids 7a-d (portion C) to obtain the 
bicyclic aldehydes 9a-i (scheme 1). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
For this transformation, catalyst 8 was employed, a Pd(N,N-Dimethyl-β-
alaninate)2 which gave better results than classic Pd-based catalysts in terms of 
yield due to its compatibility with aqueous reaction environments136. 
Scheme 1 Step 1 in the synthesis of the library 
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The second step (scheme 2) consisted of a microwave-assisted condensation 
of aldehydes 9a-i with hydrazides 10a-f to obtain the N-acylhydrazone moiety 
and achieve the final compounds 5a-p, based on a common structure which 
can ideally be subdivided into three portions (A, B, and C, as reported in 
scheme 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hydrazides 10c-f were not commercially available and were obtained by 
reaction of dihydrated NH2NH2 with the corresponding ethyl or methyl esters, 
using sealed vessel microwave heating. The synthesis of 10c-f, aldehyde 6b 
and esters 11b-c are described in the experimental section. 
After compounds 5a-c and their analogs 5d-p were obtained, they were 
evaluated for their inhibitory activity on purified human LDH-A. The compounds 
able to cause enzyme inhibition at micromolar level (5a-d, 5f-l) were also 
investigated for their activity on lactic acid production and cell proliferation on 
Raji cell line (table 1); these cells are derived from a Burkitt’s lymphoma and 
characterized by overexpression of the MYC protein. This alteration, which 
drives the neoplastic change leading to Burkitt’s lymphoma, directly alters cell 
metabolism and causes increased LDH-A levels, rendering cells very 
responsive to LDH-A inhibition137. 
 
Scheme 2 Step 2 in the synthesis of the library 
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Table 1 Activity of N-acylhydrazone analogues 5a-m and 5o on purified human 
LDH-A and on lactic acid production and cell proliferation on Raji cells. 
 
Compound 
hLDH-A 
In-cell lactate 
production 
Cell growth 
IC50 (μM)a IC50 (μM)a IC50 (μM)a 
5a 
 
37 ± 5 42 ± 3 38 ± 7 
5b  37 ± 6 > 200 n.d.
b 
5c 
 
43 ± 5 > 200 > 200 
5d 
 
n.d.b > 200 80 ± 9 
5e 
 
> 200 n.d.b n.d.b 
5f 
 
125 ± 7 134 ± 27 100 ± 10 
5g 
 
32 ± 6 52 ± 9 48 ± 14 
5h 
 
41 ± 11 105 ± 17 95 ± 27 
5i 
 
46 ± 6 >200 >200 
5j 
 
41 ± 11 >200 45 ± 15 
5k 
 
38 ± 10 100 ± 30 115 ± 14 
5l 
 
48 ± 3 115 ± 3 64 ± 9 
5m 
 
>200 n.d.b n.d.b 
5o 
 
>200 n.d.b n.d.b 
aAll points were tested in triplicate with error bars indicating the standard deviations. bNot determined. 
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Compound 5a exerted a marked effect both on lactate production in cells and 
on inhibiting purified LDH-A, thus showing a good capacity of cell penetration. 
Moreover, 5a inhibited cell growth with an IC50 of 38 µM, whereas compound 5b 
and 5c did not affect lactate production and cell growth. 
On enzymatic assays, compounds 5i-k, in which the portion A is represented 
respectively by 3-hydroxymethyl benzoyl, 5-1H indazolyl and 5-indolyl moieties, 
maintained a comparable activity to the parent compound 5a. In terms of 
binding mode, they preserved the interactions showed by compound 5a in the 
substrate binding pocket, and reached the Asp51 in the cofactor cavity. 
When portion B of 5a was replaced by 2,3 disubstituted furan or 2,5 
disubstituted thiophene rings as in compounds 5g-h, once again no change in 
the activity was observed, whereas the substitution with a 2,4 disubstituted 
pyrrole ring present in 5d, made this compound too fluorescent to be analyzed 
by fluorimetric method. The drop in potency after introduction of 2,6 
disubstituted pyridine ring in compounds 5e and 5m suggested that 6-atom 
rings may cause a different arrangement within the binding site. 
Consistently with this hypothesis, the docking results showed that 5e and 5m 
were oriented in a different way compared to the active compounds and fully 
occupied the cofactor binding site without reaching the catalytic residues. 
The modification of portion C gave conflicting results. Considering compound 
5a, the shift of the carboxylic function from the m- to the p- position, as in 
derivative 5f induced a decrease of activity. Differently, no relevant change in 
the activity was observed between compound 5b showing a p-benzoic acid and 
the analogue 5l bearing a m-benzoic acid. Finally, the esterification of 
compounds 5a-b afforded insoluble derivatives 5n and 5p, while 5o, the methyl 
ester of compound 5c, was inactive. 
Despite some evident effects on the inhibitory activity, no clear SAR pattern 
could be identified through the series described above. Considering the ability 
of 5f-l to inhibit human LDH-A, we investigated their activity on lactic acid 
production and cell proliferation on Raji cells. Compound 5g showed a cellular 
activity comparable to the one of its parent 5a. On the contrary, the other 
derivatives exhibited reduced activity in the inhibition of lactate production and 
cell growth.  
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On the basis of these results, further studies were only performed on compound 
5a. LDH-A enzymatic assays allowed to calculate the inhibition constants (Ki) vs 
pyruvate (39 µM) and NADH (47 µM) (figure 11).  
 
Further experiments were addressed at verifying the occurrence of biological 
effects usually observed in cancer cells after LDH-A inhibition. These 
experiments, which are summarized in figure 12, were performed on Raji cells 
after 18h exposure to compound 5a at 40 μM. This dose was chosen on the 
basis of the data reported on table 1 (50% inhibition on both lactate production 
and cell growth). One of the main functions of LDH-A in cancer cells is to assure 
the rapid reoxidation of NADH, needed to sustain the glycolytic process and 
other biosynthetic pathways138. Figure 12A shows that, in agreement with 
previous results obtained with other small molecule LDH-A inhibitors137,139, 
treatment with compound 5a reduced NAD+ regeneration and caused a 
statistically significant shifting of the redox balance in favor of the reduced form 
of the dinucleotide. The extent of the observed NADH increase (+ 50%) fits well 
with the effect caused by 40 μM compound 5a on lactate production in Raji cells 
(50% inhibition). 
 
 
Figure 11 Competition LDH-A assay of compound 5a versus pyruvate and NADH. The enzymatic reaction 
was evaluated through the disappearance of NADH fluorescence, which is reported in the ordinate axis as 
∆RFU/min 
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The effects caused by compound 5a on cell cycle phases distribution were 
studied by propidium iodide staining of the treated cells and subsequent flow 
cytometry analysis (figure 12B). This experiment showed that after an 18h 
treatment, compound 5A caused a small but statistically significant decrease of 
the cell fraction in S phase; on the contrary, cells in G2/M phase resulted 
significantly increased. This latter result is in agreement with published data 
obtained with oxamate140 and dichloroacetate141, a compound inhibiting 
glycolysis and lactate production. A recent investigation concerning the 
relationships between cell cycle progression and energy metabolism in cancer 
cells showed that the ATP requirement for G1 and S phases is largely met by 
accelerated glycolysis, while the energetic needs for G2/M phase are mainly 
derived from mitochondrial oxidative phosphorylation. On the basis of the 
published reports142, our flow cytometry data, indicating a reduction of the cell 
population entering S phase and an increased fraction of G2/M cells, are 
Figure 12 Experiments performed on Raji cell cultures treated with compound 5a. A: Evaluation of 
NAD/NADH balance; B: Analysis of cell cycle phases by flow cytometry; C: Apoptosis evaluation; D: 
effect of compound 5a on cell viability of Raji cultures and normal lymphocytes 
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compatible with effects exerted at the glycolytic level and can be a further 
evidence of the LDH-A inhibiting activity of compound 5a. 
To assess whether the effect of compound 5a was not only limited to cell growth 
arrest, we evaluated the expression of apoptosis markers (figure 12C). The 
evaluated proteins (BAX and BCL2) are well studied regulators of the 
mitochondrial apoptosis pathway143. Moreover, increased BAX levels were 
already found in cancer cells treated with oxamate140 and other LDH 
inhibitors144. As shown in figure 12C, an 18h treatment with compound 5a did 
not substantially alter the level of BCL2 protein, but caused a 6.7-fold increase 
in BAX expression, denoting the induction of cell death signaling. Interestingly, 
contrary to oxamate, which was observed to trigger the mitochondrial apoptosis 
pathway in cells after a prolonged period of exposition (48h)140, the effects 
caused by compound 5a on Raji cultures appeared to occur at earlier time. 
A further experiment with compound 5a was aimed at evaluating its potential in 
combination tests with commonly used chemotherapeutic agents. Compound 5a 
(40 μM) was tested on Raji cells in combination with four anticancer drugs 
usually employed in the therapy of hematological neoplasms. For each drug, we 
previously determined the lowest dose level causing statistically significant 
effects on cell viability at 24h. This dose was subsequently tested in association 
with compound 5a to calculate the combination index, according to the 
procedure described in the experimental section. A result ranging from 0.8 to 
1.2 is indicative of additive effects (table 2). As already observed in LDH 
inhibition by oxamate or after LDH-A silencing, compound 5a showed the 
potential of increasing the therapeutic efficacy of commonly used 
chemotherapeutic agents. 
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Finally, we compared the effects on cell viability caused by compound 5a on 
Raji cells and on normal lymphocytes, one of the cell populations more 
susceptible to the adverse effects of anticancer chemotherapy. The results are 
shown in figure 12C and they underline that no statistically significant effect 
was found on normal cell viability even at the dose of 200 μM.  
Although preliminary, all the obtained results were in support of the LDH 
inhibitory effect of compound 5a; they also suggested a good tolerability of the 
molecule on normal lymphocytes and its capability of improving the effects of 
commonly administered chemotherapy. 
 
 
 
 
 
 
 
 
 
 
 
Chemotherapeutic 
agent 
Combination 
Indexa 
Cisplatin 1.00 ± 0.02 
Daunomycin 0.88 ± 0.15 
Etoposide 0.86 ± 0.01 
Sunitinib 1.08 ± 0.01 
Table 2 Association compound 5a with 
chemotherapeutic agents.  
aAssociation experiments were repeated twice. A 
result ranging from 0.8 to 1.2 is indicative of 
additive effects 
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2.3 Conclusion 
In continuation of our research for innovative antitumor lead candidates, through 
a VS campaign followed by SAR studies, we identified a new class of LDH-A 
inhibitors in a series of N-acylhydrazone derivatives. The new molecules were 
active at the micromolar range on purified LDH-A; notably 5a showed a marked 
effect on lactate production in cells at the same concentration inhibiting purified 
LDH-A. A more detailed characterization of its biological properties confirmed 5a 
to be a suitable lead structure in the field of LDH-A inhibitors. Noteworthy, from 
a medicinal chemistry point of view, the N-acylhydrazone scaffold is a privileged 
structure, in which the biological relevance meets the synthetic accessibility, 
allowing to rapidly obtain variously substituted analogues, making the follow-up 
studies of the identified hits more efficient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
35 
 
2.4 Experimental section  
2.4.1 General Methods 
Reaction progress was monitored by TLC on pre-coated silica gel plates 
(Kieselgel 60 F254, Merck) and visualized by UV254 light. Flash column 
chromatography was performed on silica gel (particle size 40-63 μM, Merck). If 
required, solvents were distilled prior to use. All reagents were obtained from 
commercial sources and used without further purification. When stated, 
reactions were carried out under an inert atmosphere. Reactions involving 
microwave irradiation were performed using a microwave synthesis system 
(CEM Discover® SP, 2.45 GHz, maximum power 300 W), equipped with infrared 
temperature measurement. Compounds were named relying on the naming 
algorithm developed by CambridgeSoft Corporation and used in Chem-BioDraw 
Ultra 15.0. 1H-NMR and 13C-NMR spectra were recorded on Varian Gemini at 
400 MHz and 100 MHz respectively. Chemical shifts (δH) are reported relative to 
TMS as internal standard.  
 
2.4.2 Synthetic procedures 
General procedure for the Suzuki coupling reaction to obtain 9a-g  
To a solution of the appropriate bromo-substituted five or six membered 
heterocyclic aldehydes 6a-e (1.0 mmol) in EtOH/H2O 5:3 (tot 12 mL) in a 35 mL 
CEM microwave vessel, the correspondent carboxyphenyl boronic acids 7a-b 
(1.2 mmol), Na2CO3 2M (2.0 mmol) and Pd(N,N-Dimethyl β-alaninate)2 (5 
mol%) were added. The vessel was capped and placed in a microwave reactor 
and the reaction carried out with the following method in dynamic mode: 120°C, 
5 min, 100W, with high stirring. After completion the vessel was allowed to cool 
to room temperature, HCl 2M was added until pH turned acidic, and the mixture 
was extracted with EtOAc (3 X 10 mL). The organic phase was collected, dried 
over anhydrous Na2SO4, and the solvent evaporated under vacuum. The crude 
product was then purified via silica gel column chromatography (CH2Cl2/MeOH 
elution gradient from a 100/0 ratio to a 90/10 ratio) to obtain the pure 
compounds (yield 58-81%). 
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3-(5-formylfuran-2-yl)benzoic acid 9a 
The product was prepared using the general procedure starting 
from 6a and 7a (yield 70%). 1H NMR (DMSO-d6) δ 13.10 (bs, 1H), 9.66 (s, 1H), 
8.24 (s, 1H), 8.06 (d, J = 8.4 Hz, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.88 (t, J = 8.4 
Hz, 1H), 7.69 (d, J = 3.7 Hz, 1H), 7.45 (d, J = 3.7 Hz, 1H). 13C NMR (DMSO-d6) 
δ 178.49, 167.11, 157.50, 152.30, 132.41, 130.61, 129.91, 129.55, 129.45, 
125.75, 125.49, 109.87 ppm. 
 
3-(4-formyl-1H-pyrrol-2-yl)benzoic acid 9b 
The product was prepared using the general Suzuki coupling 
procedure starting from 6b and 7a (pale yellow solid, yield 66%). 
1H NMR (DMSO-d6) δ 13.76 (bs, 1H), 13.16 (s, 2H), 10.50 (s, 1H), 9.06 (s, 1H), 
8.72 (d, J = 7.6 Hz, 1H), 8.60 (d, J = 7.6 Hz, 1H), 8.55 (s, 1H), 8.29 (d, J = 6.0 
Hz, 1H), 7.74 (t, J = 7.6 Hz, 1H) ppm. 
 
4-(5-formylfuran-2-yl)benzoic acid 9c 
The product was prepared using the general Suzuki coupling 
procedure starting from 6a and 7b (pale yellow solid, yield 75%). 1H NMR 
(DMSO-d6) δ 13.13 (bs, 1H), 9.66 (s, 1H), 8.05 (d, J = 8.4 Hz, 2H), 8.00 (d, J = 
8.4 Hz, 2H), 7.69 (d, J = 3.7 Hz, 1H), 7.45 (d, J = 3.7 Hz, 1H); 13C NMR (DMSO-
d6) δ 178.77, 167.15, 157.31, 152.06, 133.23, 130.56, 125.43, 124.77, 110.30 
ppm. 
 
3-(5-formylfuran-3-yl)benzoic acid 9d 
The product was prepared using the general Suzuki coupling 
procedure starting from 6c and 7a (pale yellow solid, yield 58%). 1H NMR 
(DMSO-d6) δ 13.12 (bs, 1H), 9.66 (s, 1H), 8.74 (s, 1H), 8.22 (d, J = 13.9 Hz, 
1H), 8.10 (s, 1H), 8.01 – 7.85 (m, 2H), 7.61 – 7.53 (m, 1H) ppm. 
 
3-(5-formylthiophen-2-yl)benzoic acid 9e 
The product was prepared using the general Suzuki coupling 
procedure starting from 6d and 7a (pale yellow solid, yield 74%). 1H NMR 
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(DMSO-d6) δ 13.09 (bs, 1H), 9.94 (s, 1H), 8.26 (s, 1H), 8.07 (d, J = 3.7 Hz, 1H), 
8.05 (d, J = 7.7 Hz, 1H), 7.99 (d, J = 7.7 Hz, 1H), 7.85 (d, J = 3.7 Hz, 1H), 7.63 
(t, J = 7.7 Hz, 1H); 13C NMR (DMSO-d6) δ 184.58, 167.11, 151.64, 142.90, 
139.59, 133.23, 132.37, 130.83, 130.50, 130.26, 126.97, 126.46 ppm. 
 
3-(6-formylpyridin-2-yl)benzoic acid 9f 
The product was prepared using the general Suzuki coupling 
procedure starting from 6e and 7a (white solid, yield 74%). 1H NMR (DMSO-d6) 
δ 13.18 (bs, 1H), 10.10 (s, 1H), 8.77 (s, 1H), 8.42 (d, J = 8.0 Hz, 1H), 8.36 (d, J 
= 7.9 Hz, 1H), 8.17 (t, J = 8.0 Hz, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.94 (d, J = 7.9 
Hz, 1H), 7.69 (t, J = 7.9 Hz, 1H); 13C NMR (DMSO-d6) δ 194.07, 167.57, 
156.14, 152.71, 139.42, 138.26, 132.12, 131.37, 130.80, 129.71, 127.97, 
125.34, 121.10 ppm. 
 
4-(6-formylpyridin-2-yl)benzoic acid 9g 
The product was prepared using the general Suzuki coupling 
procedure starting from 6e and 7b (white solid, yield 81%).1H NMR (DMSO-d6) 
δ 13.05 (bs, 1H), 10.06 (s, 1H), 8.35 (d, J = 7.8 Hz, 1H), 8.29 (d, J = 8.4 Hz, 
2H), 8.16 (t, J = 7.8 Hz, 1H), 8.07 (d, J = 8.4 Hz, 2H), 8.02 (d, J = 7.8 Hz, 1H); 
13C NMR (DMSO-d6) δ 194.03, 167.80, 155.99, 152.73, 141.73, 139.55, 
133.24, 130.31, 129.66, 129.04, 127.33, 125.78, 121.37 ppm. 
 
General procedure for the Suzuki coupling reaction to obtain 9h-i  
To a solution of the appropriate bromo-substituted heterocyclic aldehydes 6a 
(1.0 mmol) in EtOH/H20 5:3 (tot 12 mL) in a 35 mL CEM microwave vessel, the 
correspondent boronic acids 7c-d (1.2 mmol), Na2CO3 2M (2.0 mmol) and 
Pd(N,N-Dimethyl β-alaninate)2 (5 mol%) were added. The vessel was capped 
and placed in a microwave reactor and the reaction carried out with the 
following method in dynamic mode: 120°C, 10 min, 50W, with high stirring. After 
completion the vessel was allowed to cool to room temperature and the mixture 
was extracted with EtOAc (3 X 10 mL). The organic phase was collected, dried 
over anhydrous Na2SO4, and the solvent evaporated under vacuum. The crude 
product (containing a small portion of the ethyl ester as a transesterification 
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product) was then purified via silica gel column chromatography (petroleum 
ether/EtOAc elution gradient from a 90/10 ratio to a 80/20 ratio) to obtain the 
pure compounds (yield 73-77%). 
 
Methyl 3-(5-formylfuran-2-yl)benzoate 9h 
The product was prepared using the general Suzuki coupling 
procedure starting from 6a and 7c (white solid, yield 77%). 1H NMR (CDCl3) δ 
9.68 (s, 1H), 8.45 (s, 1H), 8.06 (t, J = 7.8 Hz, 1H), 8.02 (d, J = 7.8 Hz, 1H), 7.53 
(t, J = 7.8 Hz, 1H), 7.34 (d, J = 3.7 Hz, 1H), 6.93 (d, J = 3.7 Hz, 1H), 3.96 (s, 
3H) ppm. 
 
Methyl 4-(5-formylfuran-2-yl)benzoate 9i 
The product was prepared using the general procedure starting 
from 6a and 7d (white solid, yield 73%). 1H NMR (CDCl3) δ 9.70 (s, 1H), 8.11 
(d, J = 8.6 Hz, 2H), 7.89 (d, J = 8.6 Hz, 2H), 7.34 (d, J = 3.7 Hz, 1H), 6.96 (d, J 
= 3.7 Hz, 1H), 3.94 (s, 3H); 13C NMR (DMSO-d6) δ 178.67, 166.06, 157.08, 
152.69, 133.09, 130.42, 125.54, 125.40, 111.12, 52.56 ppm. 
 
General procedure for the synthesis of hydrazides 10c-f  
A solution of the appropriate ethyl or methyl esters 11a-d (1.0 mmol) in 
methanol (5 mL) was prepared in a 10 mL CEM microwave vessel. Hydrazine 
hydrate 50% (5.0 mmol) was added, the vessel was capped and placed in a 
microwave reactor and the reaction carried out with the following method in 
dynamic mode: 140°C, 60 min, 100W, with high stirring. After completion the 
reaction mixture was transferred to a round bottom flask and the solvent 
evaporated under reduced pressure. The crude product was transferred to an 
Erlenmeyer flask and suspended in dichloromethane, heated at 50°C for 5 
minutes, rapidly vacuum filtered and washed with the same solvent, to obtain 
the pure product (yield 85-99%). When the product was found to be still not 
pure, the purification procedure was repeated. 
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Nicotinic hydrazide 10c 
The product was prepared using the general procedure for the 
synthesis of hydrazides starting from ethyl ester 11a (white solid, yield 93%). 1H 
NMR (DMSO-d6) δ 9.95 (s, 1H), 8.96 (d, J = 2.2 Hz, 1H), 8.69 (dd, J = 4.8, 1.6 
Hz, 1H), 8.15 (ddd, J = 8.0, 2.2, 1.6 Hz, 1H), 7.49 (dd, J = 8.0, 4.8 Hz, 1H), 4.65 
(bs, 2H) ppm. 
 
3-(hydroxymethyl)benzohydrazide 10d 
The product was prepared using the general procedure for the 
synthesis of hydrazides starting from ethyl ester 11b (white solid, yield 99%). 1H 
NMR (DMSO-d6) δ 9.73 (bs, 1H), 7.78 (s, 1H), 7.67 (d, J = 7.6 Hz, 1H), 7.45 (d, 
J = 7.6 Hz, 1H), 7.38 (t, J = 7.6 Hz, 1H), 5.26 (t, J = 5.7 Hz, 1H), 4.54 (bs, 2H), 
4.53 (d, J = 5.7 Hz, 2H) ppm. 
 
1H-indazole-5-carbohydrazide 10e 
The product was prepared using the general procedure for the 
synthesis of hydrazides starting from ethyl ester 11c (white solid, 95% yield). 1H 
NMR (DMSO-d6) δ 12.52 (s, 1H), 9.52 (s, 1H), 8.38 (s, 1H), 7.98 (s, 1H), 7.89 
(d, J = 8.5 Hz, 1H), 7.40 (d, J = 8.5 Hz, 1H), 4.49 (bs, 2H) ppm. 
 
1H-indole-5-carbohydrazide 10f 
The product was prepared using the general procedure for the 
synthesis of hydrazides starting from ethyl ester 11d (yield 85%). 1H NMR 
(DMSO-d6) δ 11.28 (s, 1H), 9.54 (s, 1H), 8.08 (s, 1H), 7.59 (d, J = 8.4 Hz, 1H), 
7.35-7.43 (m, 2H), 6.50 (s, 1H), 4.49 (bs, 2H) ppm. 
 
Methyl 3-(hydroxymethyl)benzoate 11b  
 
 
 
Mono-methyl isophthalate (2.0 mmol) was placed in a 50 mL round bottom flask 
and dissolved in dry THF (10 mL) under nitrogen atmosphere. The reaction 
  
40 
 
flask was placed in an ice bath to reach 0°C and 1M borane tetrahydrofuran 
complex solution (10.0 mmol) was added dropwise. After 15 minutes at 0°C the 
ice bath was removed and the reaction was stirred at room temperature 
overnight. After reaction completion ice was carefully added to the reaction, and 
the mixture extracted three times with diethyl ether. The collected organic phase 
was washed with brine, dried over anhydrous Na2SO4, and the solvent 
evaporated in vacuum to obtain 11b (yield 97%) which needed no further 
purification. 1H NMR (CDCl3) δ 8.04 (s, 1H), 7.97 (d, J = 7.8 Hz, 1H), 7.58 (d, J 
= 7.8 Hz, 1H), 7.44 (t, J = 7.8 Hz, 1H), 4.76 (s, 2H), 3.92 (s, 3H) ppm. 
 
Ethyl 1H-indazole-5-carboxylate 11c 
 
 
 
 
 
1H-indazole-5-carboxylic acid (2.0 mmol) was placed in a 35 mL microwave 
vessel and dissolved in ethanol (10 mL) under nitrogen atmosphere. The vessel 
was placed in an ice bath to reach 0°C and thionyl chloride (10.0 mmol) was 
added slowly while stirring. After 5 minutes the vessel was placed in a 
microwave reactor and the reaction carried out with the following method in 
dynamic mode: 130°C, 60 min, 80W. After completion the reaction mixture was 
transferred to a round bottom flask, methanol was added to destroy remaining 
thionyl chloride and the solvent evaporated under reduced pressure. The crude 
product was dissolved in ethyl acetate and washed 3 times with 20% K2CO3. 
The organic phase was dried over anhydrous Na2SO4, and the solvent 
evaporated in vacuum to obtain 11c (yield 95%) which needed no further 
purification. 1H NMR (CDCl3) δ 12.40 (s, 1H), 8.35 (s, 1H), 7.96 (s, 1H), 7.85 (d, 
J = 8.9 Hz, 1H), 7.37 (d, J = 8.9 Hz, 1H), 4.23 (q, J = 7.2 Hz, 2H), 1.25 (t, J = 
7.2 Hz, 3H) ppm. 
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Synthesis of 5-bromo-1H-pyrrole-3-carbaldehyde 6c 
 
 
 
Ethyl 1H-pyrrole-3-carboxylate 
1H-pyrrole-3-carboxylic acid (2.0 mmol) was placed in a 35 mL microwave 
vessel and dissolved in ethanol (10 mL) under nitrogen atmosphere. The vessel 
was placed in an ice bath to reach 0°C and thionyl chloride (10.0 mmol) was 
added slowly while stirring. After 5 minutes the vessel was placed in a 
microwave reactor and the reaction carried out with the following method in 
dynamic mode: 130°C, 60 min, 80W. After completion the reaction mixture was 
transferred to a round bottom flask, methanol was added to destroy remaining 
thionyl chloride and the solvent evaporated under reduced pressure. The crude 
product was dissolved in ethyl acetate and washed 3 times with 20% K2CO3. 
The organic phase was dried over anhydrous Na2SO4, and the solvent 
evaporated in vacuum to obtain the product (yield 93%) which needed no 
further purification. Note: the product is sensitive to light and heat. 1H NMR 
(CDCl3) δ 9.71 (s, 1H), 8.80 (bs, 1H), 7.53 (s, 1H), 6.82 (s, 1H), 6.52 (s, 1H), 
4.19 (q, J = 7.0 Hz, 2H), 1.28 (t, J = 7.0 Hz, 3H) ppm. 
 
1H-pyrrole-3-carbaldehyde 
1H-pyrrole-3-carboxylate (2.0 mmol) was placed in a 50 mL double neck round 
bottom flask and dissolved in dry CH2Cl2 (3 mL) under nitrogen atmosphere. 
The reaction was cooled to -78°C with an acetone/CO2 bath and 1.7 M DIBAl-H 
in toluene (4.0 mmol) was added dropwise. The reaction was stirred for 30 min 
then quenched with methanol and then a saturated aqueous solution of 
Rochelle’s salt. The mixture was stirred vigorously for 5 h at 23 °C. The 
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aqueous layer was extracted with CH2Cl2 and the combined organic phase was 
dried over anhydrous Na2SO4, and the solvent evaporated in vacuum to give 
the crude alcohol. To a solution of crude alcohol in methanol (3 mL) was added 
manganese (IV) oxide (20 mmol) and the reaction was stirred vigorously 
overnight at room temperature. The mixture was then filtered through a pad of 
Celite and the filtrate was concentrated in vacuum. The residue was then 
purified via silica gel column chromatography (CH2Cl2/MeOH elution gradient 
from a 100/0 ratio to a 98/2 ratio) to obtain the pure product (yield over the two 
steps 13%). Note: the product is sensitive to light and heat. 1H NMR (CD3OD) δ 
9.66 (s, 1H), 7.57 (s, 1H), 6.85 (s, 1H), 6.58 (s, 1H) ppm. 
 
5-bromo-1H-pyrrole-3-carbaldehyde 6c 
1H-pyrrole-3-carbaldehyde (1.3 mmol) was placed in a 50 mL double neck 
round bottom flask and dissolved in dry THF (10 mL) under nitrogen 
atmosphere. The reaction was cooled to -78°C with an acetone/CO2 bath and 
stirred for 10 minutes. N-bromosuccinimide (1.3 mmol) was added, the reaction 
was let reach -50°C and that temperature was kept for 10 hours with continuous 
stirring. 2M NaOH was added to quench the reaction, followed by adding 3M 
HCl until acidic pH was reached. The reaction was extracted 3 times with diethyl 
ether, the organic phase was collected, dried over anhydrous Na2SO4, and the 
solvent evaporated in vacuum. The residue was then purified via silica gel 
column chromatography (petroleum ether/ethyl acetate elution gradient from a 
100/0 ratio to a 70/30 ratio) to obtain the pure product (yield 45%). Note: the 
product is sensitive to light and heat. 1H NMR (CDCl3) δ 9.68 (s, 1H), 8.72 (bs, 
1H), 7.38 (s, 1H), 6.66 (s, 1H) ppm. 
 
General procedure for the synthesis of N-acylhydrazones 5a-p  
A solution of the appropriate aldehydes 9a-i (1.0 mmol) in ethanol (20 mL) was 
prepared in a 35 mL CEM microwave vessel. The correspondent hydrazides 
10a-f (1.0 mmol) were added, the vessel was capped and placed in a 
microwave reactor and the reaction carried out with the following method in 
dynamic mode: 120°C, 45 min, 130W. After completion the vessel was allowed 
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to cool to room temperature and then placed in a refrigerator for 1 hour. The 
product precipitated from the cold reaction mixture was collected by vacuum 
filtration and dried on filter. Purification was achieved by recrystallization with 
methanol, yielding the pure product as a colored solid ranging from yellow to 
red color (yield 43-83%). 
 
3-(5-((2-(3,4,5-trimethoxybenzoyl)hydrazono)methyl) 
furan-2-yl)benzoic acid 5a 
The product was prepared using the general 
procedure for the N-acylhydrazone formation 
starting from 9a and 10a (pale yellow solid, yield 73%). 1H NMR (DMSO-d6) δ 
13.18 (bs, 1H), 11.74 (s, 1H), 8.45 (s, 1H), 8.33 (s, 1H), 8.01 (d, J = 7.6 Hz, 1H), 
7.91 (d, J = 7.6 Hz, 1H), 7.61 (t, J = 7.6 Hz, 1H), 7.27 (d, J = 2.6 Hz, 1H), 7.24 
(s, 2H), 7.09 (d, J = 2.6 Hz, 1H), 3.87 (s, 6H), 3.77 (s, 3H); 13C NMR (400 MHz, 
DMSO-d6) δ 166.92, 162.57, 153.75, 152.73, 149.43, 140.50, 137.30, 131.66, 
129.85, 129.49, 128.88, 128.44, 128.15, 124.36, 116.34, 109.21, 10521, 60.15, 
56.12; MS (ES): m/z 425 [M+ H]+, 447 [M+ Na]+, 463 [M+ K]+, 423 [M- H]-. Anal. 
Calcd. for C22H20N2O7 (%): C, 62.26; H, 4.75; N, 6.60. Found (%): C, 62.16; H, 
4.68; N, 6.62. 
 
4-(5-((2-(2-cyanoacetyl)hydrazono)methyl)furan-2-
yl)benzoic acid 5b 
The product was prepared using the general procedure for the N-acylhydrazone 
formation starting from 9c and 10b (red solid, yield 55%). 1H NMR (DMSO-d6, 
mixture of two cis–trans amide bond rotamers) δ 13.04 (bs, 1H), 11.84 (s, 
0.69H), 11.75 (s, 0.31H), 8.04-7.97 (m, 2H), 7.94-7.86 (m, 2H), 7.40 (d, J = 3.6 
Hz, 0.31H), 7.30 (d, J = 3.6 Hz, 0.69H), 7.12 (d, J = 3.6 Hz, 0.31H), 7.09 (d, J = 
3.6 Hz, 0.69H), 4.22 (s, 1.38H), 3.83 (s, 0.62H) ppm; 13C NMR (DMSO-d6) δ 
166.81, 164.75, 158.88, 153.89, 153.53, 149.43, 149.36, 137.14, 133.92, 
133.06, 130.08, 130.03, 129.93, 124.18, 123.90, 123.81, 116.23, 115.99, 
110.37, 40.14, 39.93, 39.72, 39.51, 39.31, 39.10, 38.89, 24.88, 24.27 ppm; MS 
(ES): m/z 298 [M+ H]+, 320 [M+ Na]+, 336 [M+ K]+, 296 [M- H]-, 332 [M+ Cl]-. 
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Anal. Calcd. for C15H11N3O4 (%): C, 60.61; H, 3.73; N, 14.14. Found (%): C, 
60.52; H, 3.60; N, 14.23. 
 
3-(5-((2-nicotinoylhydrazono)methyl)furan-2-yl)benzoic 
acid 5c 
The product was prepared using the general procedure 
for the N-acylhydrazone formation starting from 9a and 10c (pale yellow solid, 
yield 60%). 1H NMR (DMSO-d6) δ 13.22 (bs, 1H), 12.03 (s, 1H), 9.07 (s, 1H), 
8.78 (d, J = 4.2 Hz, 1H), 8.39 (s, 1H), 8.34 (s, 1H), 8.26 (d, J = 7.7 Hz, 1H), 8.05 
(d, J = 7.7 Hz, 1H), 7.92 (d, J = 7.7 Hz, 1H), 7.66 – 7.54 (m, 2H), 7.28 (d, J = 
3.3 Hz, 1H), 7.13 (d, J = 3.3 Hz, 1H) ppm; 13C NMR (DMSO-d6) δ 166.92, 
161.67, 153.94, 152.36, 149.25, 148.54, 137.84, 135.45, 131.68, 129.81, 
129.52, 129.13, 128.95, 128.23, 124.40, 123.68, 116.84, 109.25 ppm. Anal. 
Calcd. for C18H13N3O4 (%): C, 64.48; H, 3.91; N, 12.53. Found (%): C, 64.55; H, 
3.84; N, 12.67. 
 
3-(4-((2-(3,4,5-
trimethoxybenzoyl)hydrazono)methyl)-1H-pyrrol-2-
yl)benzoic acid 5d 
The product was prepared using the general 
procedure for the N-acylhydrazone formation starting from 9b and 10a (gray 
solid, yield 72%). 1H NMR (DMSO-d6) δ 13.03 (bs, 1H), 11.89 (s, 1H), 11.33 (s, 
1H), 8.37 (s, 1H), 8.26 (s, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.78 (d, J = 7.8 Hz, 1H), 
7.51 (t, J = 7.8 Hz, 1H), 7.35 (s, 1H), 7.22 (s, 2H), 6.94 (s, 1H), 3.86 (s, 6H), 
3.72 (s, 3H) ppm; 13C NMR (DMSO-d6) δ 167.71, 162.38, 153.07, 144.76, 
140.57, 132.86, 132.66, 131.90, 129.56, 129.48, 128.58, 127.42, 124.67, 
123.85, 121.30, 110.01, 105.51, 103.96, 60.54, 56.53 ppm. Anal. Calcd. for 
C22H21N3O6 (%): C, 62.41; H, 5.00; N, 9.92. Found (%): C, 62.29; H, 5.11; N, 
9.80. 
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3-(6-((2-(3,4,5-
trimethoxybenzoyl)hydrazono)methyl)pyridin-2-
yl)benzoic acid 5e 
The product was prepared using the general procedure for the N-acylhydrazone 
formation starting from 9f and 10a (white solid, yield 66%). 1H NMR (DMSO-d6) 
δ 13.12 (bs, 1H), 11.90 (s, 1H), 8.75 (s, 1H), 8.66 (s, 1H), 8.35 (d, J = 7.9 Hz, 
1H), 8.09 (d, J = 7.9 Hz, 1H), 8.06 – 7.95 (m, 3H), 7.65 (t, J = 7.9 Hz, 1H), 7.28 
(s, 2H), 3.88 (s, 6H), 3.74 (s, 3H) ppm; 13C NMR (DMSO-d6) δ 167.18, 154.92, 
153.25, 152.76, 148.22, 139.38, 138.36, 138.31, 130.64, 130.00, 129.23, 
128.20, 127.41, 120.88, 119.03, 110.70, 109.61, 105.32, 60.17, 56.16, 30.69 
ppm. Anal. Calcd. for C23H21N3O6 (%): C, 63.44; H, 4.86; N, 9.65. Found (%): C, 
63.32; H, 4.76; N, 9.60. 
 
4-(5-((2-(3,4,5-
trimethoxybenzoyl)hydrazono)methyl)furan-2-
yl)benzoic acid 5f 
The product was prepared using the general procedure for the N-acylhydrazone 
formation starting from 9c and 10a (orange solid, yield 66%). 1H NMR (DMSO-
d6) δ 12.94 (bs, 1H), 11.74 (s, 1H), 8.45 (s, 1H), 8.03 (d, J = 8.1 Hz, 2H), 7.91 
(d, J = 8.1 Hz, 2H), 7.33 (d, J = 2.3 Hz, 1H), 7.24 (s, 2H), 7.12 (d, J = 2.3 Hz, 
1H), 3.87 (s, 6H), 3.74 (s, 3H) ppm; 13C NMR (DMSO-d6) δ 167.26, 162.99, 
154.12, 153.15, 150.41, 140.99, 137.69, 133.59, 130.54, 130.33, 128.84, 
124.27, 116.65, 110.95, 110.02, 105.66, 60.58, 56.56 ppm. Anal. Calcd. for 
C22H20N2O7 (%): C, 62.26; H, 4.75; N, 6.60. Found (%): C, 62.31; H, 4.67; N, 
6.73. 
 
3-(5-((2-(3,4,5-
trimethoxybenzoyl)hydrazono)methyl)furan-3-
yl)benzoic acid 5g 
The product was prepared using the general 
procedure for the N-acylhydrazone formation starting from 9d and 10a (yellow 
solid, yield 43%). 1H NMR (DMSO-d6) δ 13.98 (bs, 1H), 11.75 (s, 1H), 8.49 (s, 
1H), 8.39 (s, 1H), 8.19 (s, 1H), 7.92 (d, J = 8.1 Hz, 1H), 7.87 (d, J = 8.1 Hz, 1H), 
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7.54 (t, J = 8.1 Hz, 1H), 7.49 (s, 1H), 7.24 (s, 2H), 3.87 (s, 6H), 3.73 (s, 3H) 
ppm; 13C NMR (DMSO-d6) δ 167.34, 162.55, 152.76, 150.56, 141.96, 140.54, 
137.19, 131.50, 129.79, 129.26, 128.38, 128.21, 127.15, 126.16, 111.84, 
105.27, 60.19, 56.17 ppm. Anal. Calcd. for C22H20N2O7 (%): C, 62.26; H, 4.75; 
N, 6.60. Found (%): C, 62.29; H, 4.80; N, 6.67. 
 
3-(5-((2-(3,4,5-
trimethoxybenzoyl)hydrazono)methyl)thiophen-2-
yl)benzoic acid 5h 
The product was prepared using the general 
procedure for the N-acylhydrazone formation starting from 9e and 10a (pale 
yellow solid, yield 68%). 1H NMR (DMSO-d6) δ 12.90 (bs, 1H), 11.74 (s, 1H), 
8.68 (s, 1H), 8.22 (s, 1H), 7.99 (d, J = 7.5 Hz, 1H), 7.91 (d, J = 7.5 Hz, 1H), 7.66 
(d, J = 3.2 Hz, 1H), 7.59 (t, J = 7.5 Hz, 1H), 7.51 (d, J = 3.2 Hz, 1H), 7.23 (s, 
2H), 3.87 (s, 3H), 3.73 (s, 2H) ppm; 13C NMR (DMSO-d6) δ 166.89, 162.48, 
152.74, 144.25, 142.68, 140.61, 138.97, 133.53, 132.16, 131.99, 129.72, 
129.70, 128.96, 128.47, 125.96, 125.10, 105.34, 60.19, 56.19 ppm. Anal. Calcd. 
for C22H20N2O6S (%): C, 59.99; H, 4.58; N, 6.36. Found (%): C, 60.04; H, 4.71; 
N, 6.26. 
 
3-(5-((2-(3-
(hydroxymethyl)benzoyl)hydrazono)methyl)furan-
2-yl)benzoic acid 5i 
The product was prepared using the general procedure for the N-acylhydrazone 
formation starting from 9a and 10d (yellow solid, yield 75%). 1H NMR (DMSO-
d6) δ 13.26 (bs, 1H), 11.91 (s, 1H), 8.67 (s, 1H), 8.42 (s, 1H), 8.35 (d, J = 11.8 
Hz, 2H), 8.07 (dd, J = 15.0, 8.0 Hz, 2H), 7.62 (dd, J = 15.0, 8.0 Hz, 2H), 7.36 (d, 
J = 2.9 Hz, 1H), 7.27 (t, J = 4.0 Hz, 1H), 7.09 (d, J = 2.9 Hz, 1H), 5.36 (t, J = 3.6 
Hz, 1H), 4.59 (d, J = 3.6 Hz, 2H); 13C NMR (DMSO-d6) δ 172.56, 168.30, 
163.63, 154.80, 149.65, 143.43, 137.73, 133.58, 130.18, 129.72, 129.37, 
129.30, 128.68, 126.31, 126.04, 124.88, 116.66, 109.06, 62.98, 21.60 ppm. 
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Anal. Calcd. for C20H16N2O5 (%): C, 65.93; H, 4.43; N, 7.69. Found (%): C, 
65.84; H, 4.34; N, 7.80. 
 
3-(5-((2-(1H-indazole-5-
carbonyl)hydrazono)methyl)furan-2-yl)benzoic acid 
5j 
The product was prepared using the general procedure for the N-acylhydrazone 
formation starting from 9a and 10e (dark yellow solid, yield 67%). 1H NMR 
(DMSO-d6) δ 13.36 (bs, 1H), 13.26 (bs, 1H), 11.93 (s, 1H), 8.43 (s, 2H), 8.34 (s, 
1H), 8.28 (s, 1H), 8.05 (d, J = 8.2 Hz, 1H), 7.91 (d, J = 8.0 Hz, 2H), 7.66 (d, J = 
8.2 Hz, 1H), 7.61 (t, J = 8.2 Hz, 1H), 7.28 (d, J = 2.8 Hz, 1H), 7.08 (d, J = 2.8 
Hz, 1H) ppm; 13C NMR (DMSO-d6) δ 166.94, 163.43, 153.61, 149.61, 141.10, 
136.72, 134.89, 131.68, 129.89, 129.49, 128.83, 128.13, 125.64, 125.53, 
124.32, 122.31, 121.22, 116.02, 110.20, 109.19 ppm. Anal. Calcd. for 
C20H14N4O4 (%): C, 64.17; H, 3.77; N, 14.97. Found (%): C, 64.24; H, 3.72; N, 
14.90. 
 
3-(5-((2-(1H-indole-5-
carbonyl)hydrazono)methyl)furan-2-yl)benzoic acid 
5k 
The product was prepared using the general procedure for the N-acylhydrazone 
formation starting from 9a and 10f (orange solid, yield 62%). 1H NMR (DMSO-
d6) δ 13.19 (bs, 1H), 11.79 (s, 1H), 11.41 (s, 1H), 8.44 (s, 1H), 8.34 (s, 1H), 
8.22 (s, 1H), 8.05 (d, J = 7.7 Hz, 1H), 7.91 (d, J = 7.7 Hz, 1H), 7.70 (d, J = 8.1 
Hz, 1H), 7.61 (t, J = 8.1 Hz, 1H), 7.51 (s, 1H), 7.49 – 7.46 (m, 1H), 7.26 (d, J = 
4.1 Hz, 1H), 7.05 (d, J = 4.1 Hz, 1H), 6.59 (s, 1H) ppm; 13C NMR (DMSO-d6) δ 
166.99, 164.16, 153.47, 149.79, 137.71, 136.16, 131.75, 129.92, 128.72, 
128.19, 128.00, 127.03, 124.55, 124.29, 120.49, 120.33, 115.78, 110.95, 
109.61, 109.06, 102.36, 102.14 ppm. Anal. Calcd. for C21H15N3O4 (%): C, 67.56; 
H, 4.05; N, 11.25. Found (%): C, 67.61; H, 4.13; N, 11.16. 
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3-(5-((2-(2-cyanoacetyl)hydrazono)methyl)furan-2-
yl)benzoic acid 5l 
The product was prepared using the general procedure 
for the N-acylhydrazone formation starting from 9a and 10b (orange solid, yield 
74%). 1H NMR (DMSO-d6, mixture of two cis–trans amide bond rotamers) δ 
13.12 (bs, 1H), 11.81 (s, 0.63H), 11.72 (s, 0.37H), 8.27 (s, 1H), 8.01 (d, J = 7.9 
Hz, 1H), 7.91 (s, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.58 (t, J = 7.9 Hz, 1H), 7.24 (d, 
J = 3.3 Hz, 1H), 7.08 (d, J = 3.3 Hz, 0.37H), 7.05 (d, J = 3.3 Hz, 0.63H), 4.20 (s, 
1.26H), 3.81 (s, 0.74H) ppm; 13C NMR (DMSO-d6) δ 166.92, 164.71, 153.71, 
148.91, 137.29, 134.22, 131.67, 129.79, 129.53, 128.95, 128.12, 124.40, 
116.23, 116.00, 109.18, 24.89, 24.28 ppm. Anal. Calcd. for C15H11N3O4 (%): C, 
60.61; H, 3.73; N, 14.14. Found (%): C, 60.49; H, 3.82; N, 14.03. 
 
4-(6-((2-(2-cyanoacetyl)hydrazono)methyl)pyridin-2-
yl)benzoic acid 5m 
The product was prepared using the general 
procedure for the N-acylhydrazone formation starting from 9g and 10b (white 
solid, yield 83%). 1H NMR (DMSO-d6, mixture of two cis–trans amide bond 
rotamers) δ 13.08 (bs, 1H), 12.10 (s, 0.77H), 11.99 (s, 0.23H), 8.26 (s, 1H), 8.23 
(d, J = 7.9 Hz, 2H), 8.09 (m, 3H), 8.01 (d, J = 7.9 Hz, 2H), 4.30 (s, 1.54H), 3.89 
(s, 0.46H) ppm; 13C NMR (DMSO-d6) δ 167.49, 165.64, 155.24, 153.22, 
145.09, 142.30, 138.60, 131.72, 130.25, 127.14, 121.92, 119.72, 116.37, 
109.99, 24.75 ppm. Anal. Calcd. for C16H12N4O3 (%): C, 62.33; H, 3.92; N, 
18.17. Found (%): C, 62.44; H, 3.87; N, 18.20. 
 
Methyl 3-(5-((2-(3,4,5-
trimethoxybenzoyl)hydrazono)methyl)furan-2-
yl)benzoate 5n 
The product was prepared using the general 
procedure for the N-acylhydrazone formation starting from 9h and 10a (pale 
yellow solid, yield 68%). 1H NMR (DMSO-d6) δ 11.72 (s, 1H), 8.46 (s, 1H), 8.33 
(s, 1H), 8.08 (d, J = 7.6 Hz, 1H), 7.94 (d, J = 7.6 Hz, 1H), 7.64 (t, J = 7.8 Hz, 
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1H), 7.30 (d, J = 3.3 Hz, 1H), 7.24 (s, 2H), 7.10 (d, J = 2.4 Hz, 1H), 3.92 (s, 3H), 
3.87 (s, 6H), 3.74 (s, 3H) ppm; 13C NMR (DMSO-d6) δ 165.81, 159.99, 152.70, 
149.49, 137.32, 131.28, 130.48, 129.97, 129.66, 128.69, 127.61, 123.96, 
120.24, 116.34, 110.98, 109.41, 106.37, 105.21, 60.12, 56.90, 56.11, 55.61, 
52.34 ppm. Anal. Calcd. for C23H22N2O7 (%): C, 63.01; H, 5.06; N, 6.39. Found 
(%): C, 63.12; H, 5.00; N, 6.42. 
 
Methyl 3-(5-((2-nicotinoylhydrazono)methyl)furan-2-
yl)benzoate 5o 
The product was prepared using the general procedure 
for the N-acylhydrazone formation starting from 9h and 10c (white solid, yield 
48%). 1H NMR (DMSO-d6) δ 12.03 (s, 1H), 9.07 (s, 1H), 8.78 (d, J = 6.0 Hz, 
1H), 8.40 (s, 1H), 8.33 (s, 1H), 8.26 (d, J = 7.8 Hz, 1H), 8.09 (d, J = 7.8 Hz, 1H), 
7.94 (d, J = 8.2 Hz, 1H), 7.65 (t, J = 8.2 Hz, 1H), 7.61 – 7.55 (m, 1H), 7.31 (d, J 
= 3.5 Hz, 1H), 7.14 (d, J = 3.5 Hz, 1H), 3.92 (s, 3H) ppm; 13C NMR (DMSO-d6) 
δ 165.55, 164.23, 161.56, 153.82, 152.26, 149.29, 148.50, 137.89, 135.45, 
130.50, 129.82, 129.04, 128.55, 128.48, 124.02, 123.72, 117.08, 109.57, 30.66 
ppm. Anal. Calcd. for C19H15N3O4 (%): C, 65.32; H, 4.33; N, 12.03. Found (%): 
C, 65.38; H, 4.45; N, 11.97. 
 
Methyl 4-(5-((2-(2-
cyanoacetyl)hydrazono)methyl)furan-2-yl)benzoate 
5p 
The product was prepared using the general procedure for the N-acylhydrazone 
formation starting from 9i and 10b (orange solid, yield 53%). 1H NMR (DMSO-
d6) δ 11.89 (s, 1H), 8.42 (s, 1H), 8.05 (d, J = 7.7 Hz, 2H), 7.95 (d, J = 7.7 Hz, 
2H), 7.35 (d, J = 3.8 Hz, 1H), 7.15 (d, J = 3.8 Hz, 1H), 3.89 (s, 3H), 3.87 (s, 2H) 
ppm; 13C NMR (DMSO-d6) δ 178.28, 165.73, 165.67, 156.58, 149.85, 133.43, 
132.65, 129.98, 125.11, 124.83, 124.03, 111.93, 110.75, 109.54, 52.27, 30.63 
ppm. Anal. Calcd. for C16H13N3O4 (%): C, 61.73; H, 4.21; N, 13.50. Found (%): 
C, 61.65; H, 4.26; N, 13.56. 
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CHAPTER 3 
 
Synthesis of galloflavin analogs and their evaluation as lactate 
dehydrogenase A inhibitors 
 
 
3.1 Introduction 
Galloflavin (GF) is a tricyclic compound based on a trihydroxy-substituted 
isocoumarin core, [c] fused with a hydroxypyranone ring (figure 13 compound 
12). 
It is strictly related to gallic acid (GA), which is currently its sole synthetic 
precursor, leading to GF in a one-step dimerization/oxidation process mediated 
by NaOH132,145. 
 
 
 
 
 
In scheme 3 a hypothesis for the mechanism involved in the formation of GF 
through reaction of GA with NaOH in air is shown. The steps have not been 
investigated and the mechanism is only inspired by previous work on the 
oxidation and degradation of GA in natural matrixes146–148. 
Used initially as a yellow mordant dye, GF was first prepared together with 
some protected analogs by Bohn and Graebe in 1887149, as a compound with 
unknown structure and molecular formula C13H6O9. Later studies by 
Herzig150,151 and Haworth145 disclosed that the actual formula is C12H6O8 and 
proposed the structure that we know today, which has only recently been 
confirmed by our group with NMR and MS132; in this study, published in 
collaboration with the groups of Prof. Di Stefano and Prof. Recanatini, GF was 
identified as a potential LDH inhibitor through a structure-based virtual 
screening carried out comparing compounds of the NCI Diversity Set.  
Figure 13 Molecular structures of galloflavin, gallic acid and isocoumarin 
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After an initial evaluation on the human LDH-A isolated enzyme to assess 
inhibition of enzyme activity, GF was tested on different cancer cell lines. It was 
found to inhibit both the enzymatic activity and lactate production in cancer cells 
proving good cell permeability132. 
Since then, GF has been considered as a reference compound among the 
anticancer glycolytic inhibitors, and is now produced and sold by Sigma-Aldrich. 
Several studies focusing on the discovery of new LDH inhibitors used the 
comparison with GF as a prove for efficacy152,153. Other investigations focused 
on its activity on  different cancer cell lines and its mechanism of action on a 
molecular level134,137,144,154–156. Notably, a 2D in-cell NMR metabolomics study 
recently revealed that not only GF inhibits LDH, but it could exert a multi-target 
effect including influence on PDK, ALT1 and PDH, thus leading the authors to 
suggest that GF should be also defined as a “functional inhibitor” of PDK and 
ALT1 and a “functional activator” of PDH157. 
Scheme 3 Hypothesis of GF formation mechanism through dimerization/oxidation of gallic acid. Some 
steps are simplified for clarity and proton transfers are arbitrary 
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An additional study by Prof. Di Stefano’s group demonstrated that GF sensitizes 
lymphoma cells to cisplatin without enhancing its effects on normal 
lymphocytes, therefore giving further prove of the great potential of this 
compound in the field of anticancer drug discovery158. 
Despite a calculated binding pose was postulated in the initial study as reported 
in figure 14, GF was never really investigated in terms of SAR, in order to gain 
a deeper understanding of the role of its key functional groups when binding to 
the enzyme. 
 
 
 
 
 
 
 
 
 
 
 
The reason behind this lies in the peculiar physico-chemical properties of the 
compound and its unpredictable reactivity. In fact, GF has a poor solubility in 
DMSO (1.7g/100mL) and water, making it hard to handle for biological tests and 
unsuitable under a pharmacokinetic point of view; it is furthermore unstable in 
acidic or basic environments and highly refractory to any functionalization. 
All these aspects account for a molecule which, despite its promising efficacy as 
a ligand, has no future as a drug and requires a SAR study to understand the 
way it binds in order to develop “user friendly” analogs with comparable or 
higher affinity to the LDH-A site. Due to the mechanism illustrated in scheme 3, 
it didn’t seem practical to obtain analogs with the same core structure and 
through the same synthetic way. On the contrary, since most likely the key 
factors in GF activity are the number and position of its hydrogen bond donors 
and acceptors, we decided to carry out a study to develop new compounds 
carrying the same pharmacophores mounted on a different scaffold, thus 
Figure 14 Original calculated binding pose of galloflavin 
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creating a model system with synthetic accessibility and improved physico-
chemical properties which could help us explore the structure-activity 
relationship of galloflavin without having to deal with its major drawbacks. 
We therefore begun a process of structural simplification and rationalization of 
galloflavin, analyzing its features and trying to reduce to the minimum its main 
elements of synthetic and structural complexity. 
One of the key factors driving the design of the new inhibitors was the presence 
on GF of an unusual fusion of two 2-pyrone rings (red portion in figure 15); this 
element was believed to bring unnecessary complexity and pose significant 
synthetic challenges without being crucial for the compound’s activity. The 
carbonyl oxygen of the lactone on the 2 position was originally calculated to be 
involved in a H-bond in the 2012 paper132, but its actual contribution was still 
uncertain so it was considered nonessential to the purposes of our research. 
Specific attention was posed on the need to keep the same position and 
distance for the 4 OH groups, to reproduce to the best the H-bond fingerprint of 
GF. A tricyclic system was not intrinsically necessary but it proved to be useful 
in mimicking the original structure, together with the lactone on the 6 position, 
which emerges directly from the gallic acid building block, and also allows for 
the introduction of the typical trihydroxy substitution pattern on the A ring. 
Finally, an effort was done in making the synthesis fast and modular, in order to 
establish a well-tested path to the future synthesis of analogs by simply 
employing different commercial building blocks. 
 
 
 
 
 
 
As a results of the considerations summarized above, a series of novel 
compounds was identified, and a synthetic study was carried out to obtain the 
Figure 15 Illustration of the main concepts driving the structural simplification of galloflavin 
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first structural analogs of galloflavin with postulated LDH inhibitory activity. The 
compounds are reported in figure 16 and they constituted the initial goal of the 
project due to their promising similarity to GF. 
 
 
 
 
 
 
 
 
 
Compound 15 is also known as urolithin M6 (UM6) and since the beginning it 
led the ranking due to its higher structural similarity. Compound 16 is the natural 
product norbergenin, demethylated derivative of bergenin, both isolated from 
several species of plants from the genus Bergenia, and characterized by a β-D-
glucosyl residue C-linked to gallic acid in the ortho position, with the carboxyl 
group forming a δ-lactone with the C-2 hydroxyl group of the glucose moiety. 
Despite its structural complexity, 16 was listed among the target compounds 
due its synthetic accessibility, through demethylation of the commercially 
available bergenin. 17 is a reduced analog of 15 and it was designed to assess 
the role of the carbonyl on the 6 position. Compound 18 is the only compound 
not featuring a tricyclic structure; this allows for the exploration of the role of the 
core of galloflavin, and the relevance of its geometrical flatness, while keeping 
fixed the position of the OH in 3, regardless of the dihedral angle formed by the 
byphenyl system. The phenanthrene derivative 19 is a full carbocycle bringing 
the highest possible structural simplification, removing any potential influence of 
heteroatoms on the core scaffold. 
The role of UM6 was crucial in the project for three reasons: the compound has 
been identified as a recurrent metabolite after the assumption of aliments rich in 
ellagitannins, such as pomegranate juice159–161, and together with the other 
Figure 16 The 5 compounds that were designed to mimic the inhibitory activity of GF with a simplified 
structure 
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urolithins (figure 17) it has been attributed a number of beneficial properties 
and biological activities162–165, but despite its relevance a reproducible synthetic 
approach was never published; the origin of urolithins and their common 
presence in gut microbiota suggested a promising safety profile; the structural 
similarity with galloflavin is high and it represents a useful tool to explore the 
substitution pattern on the rings affecting minimally the influence of the scaffold. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other urolithins have been synthesized before and for some of them fast and 
effective strategies are available in literature. Synthetic access is important for 
this class of compounds since they are needed as standards for their analytical 
determination. 
Usual routes to the bezo[c]chromenone scaffold shared by all urolithins can be 
summarized into three main strategies: 1) copper catalyzed Hurtley reaction 
between an ortho- brominated benzylic acid derivative and resorcinol166; 2) 
basic decarboxylative hydrolysis of ellagic acid (EA)167; 3) inverse electron 
demand Diels–Alder between a coumarin-derived diene and the enamine 
resulting from the condensation of dimethoxyacetaldehyde and pyrrolidine168. 
Figure 17 Structures and classification of some of the most common urolithins 
that are detectable in human microbiota after ingestion of ellagitannin-rich foods 
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All these methods have some major drawbacks, as summarized in figure 18, 
and none of them is really suitable for the synthesis of UM6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Hurtley reaction is a fast and inexpensive route to some of the simpler 
urolithins (M1 to M4) but unfortunately it doesn’t work with gallic acid derivatives 
and it furthermore presents issues of low yields in both the main step and 
deprotection; hydrolysis of EA permits to achieve urolithin M5 according to 
literature, but no other known compounds are obtainable through this route and 
besides, in our hands, the only outcome that this reaction produced was 
extensive degradation of the starting material; the Diels-Alder route is highly 
substrate-dependent and has narrow applicability since it was designed solely 
for the synthesis of urolithin M7, and even though it might potentially be 
adjusted to broaden its scope, it is expensive in terms of both starting materials 
and number of steps. 
A new synthesis was therefore needed to obtain and test UM6 and the novel 
compounds 17 and 19, as well as future analogs. I will then hereafter describe 
the rational design and the planning process for the synthetic strategy. 
Figure 18 Current methods for the synthesis of urolithins 
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Complementing the chemical synthesis, the collaboration of Prof. Di Stefano 
and collaborators once again granted the obtainment of the necessary 
biological data. 
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3.2 Results and discussion 
The synthetic strategies devised in the early phase were based on two 
disconnection patterns which lead to the same starting material through 
different intermediates. 
It seemed clear since the beginning that GA would be an ideal starting point 
since the evident presence of its molecular outline inside the structure of UM6. 
Route A (scheme 4) starts with the disconnection of the O-aryl bond in the 
lactone ring which can be formed through a C-H oxygenation, the biphenyl 
intermediate is then obtained through a Suzuki coupling between the 
appropriate boronic acid and a halogenated GA analog, which in turn is formed 
by simple halogenation of GA. 
Route B is a logical inversion of the first two disconnections of route A, with the 
aryl-aryl bond being formed through a Heck coupling and the ester moiety being 
obtained by esterification between a resorcinol derivative and the halogenated 
GA. 
The presence of several OH moieties required the use of suitable protecting 
groups, which were widely screened on both routes to optimize bulkiness, 
stability of the PG and reactivity of the substrates in the key steps. 
The forward synthesis planned for route A is reported in scheme 5 and it 
features the use of a methyl ester and OH-protected GA derivative which is 
brominated, coupled with the OH-protected para-arylboronic acid and in turn 
hydrolyzed with a Brønsted base to give the free acid which is transformed into 
Scheme 4 Two hypothesis of retrosynthesis for urolithin M6 
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lactone through persulfate-mediated C-O oxygenation, followed by deprotection 
to achieve the desired product.  
Route B (scheme 6) goes through bromination and hydrolysis of the starting 
material, Steglich esterification with a monoprotected resorcinol, ring closing 
through Heck coupling and final deprotection. 
 
 
 
 
 
 
 
 
 
 
The protecting groups screened are reported in table 3, together with the 
corresponding outcome for each route. Methyl ether was eventually identified as 
the best PG, despite the relatively harsh conditions required for its deprotection 
which is also achieved in not excellent yield, since the other options presented 
serious problems in terms of stability of PGs or reactivity of the substrates. The 
Scheme 5 Planned synthetic scheme for route A to UM6 
Scheme 6 Planned synthetic scheme for route B to UM6 
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compound was obtained after deprotection of the methylated UM6, initially as a 
mixture of compounds, probably because of the presence of a residual 
monomethylated compound that was inseparable from the desired product with 
normal flash chromatography. 
 
PG 
Outcome on route 
A 
Outcome on route 
B 
O-
Me 
Product obtained 
after C18 purification 
/ 
O-iPr / 
Degradation after 
deprotection 
O-
MOM 
Unsuccesful 
protection of SM 
(gallic acid) 
Unsuccesful 
protection of SM 
(gallic acid) 
O-Bn 
No reactivity in key 
reaction (C-H ox.) 
Degradation after 
deprotection 
O-Ac Unstable PG 
No reactivity in key 
reaction (Heck) 
 
Attempts to purify the final mixture with C18 flash silica were successful and 
afforded the desired product UM6 as a pure compound. 
Once the ideal PG had been identified using a standard set of unoptimized 
reaction conditions, a screening was carried out to optimize yields and reaction 
times in the key steps of both routes. 
 
 
 
 
 
 
 
 
 
 
 
 
Catalyst Base Solvent MW/pTube Yield  
Pd(N,N-
Dimethyl--
alaninate)2 
K2CO3 
EtOH/H2O 
5/3 
MW (1h) 35% 
Pd(N,N-
Dimethyl--
alaninate)2 
K3PO4 Toluene MW (1h) 40% 
Pd(OAc)2 K3PO4 Toluene MW (1h) 42% 
Pd(PPh3)4 K3PO4 
DME/H2O 
6/1 
MW (1h) 56% 
Pd(PPh3)4 K3PO4 DME MW (1h) 74% 
Pd(PPh3)4 K3PO4 DME 
pTube 
(24h) 
82% 
Table 4 Screening of reaction conditions for the Suzuki coupling (route A) 
Table 3 Screening of protecting groups 
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Table 4 summarizes the screening for the Suzuki coupling in route A, where 
different catalysts, bases, solvents and heat sources were assessed. The best 
results were obtained using Pd(PPh3)4 as catalyst, K3PO4 as base and DME as 
solvent in a pressure tube with conventional heating for 24 hours, affording a 
yield of 82%. The same set of conditions used with microwave heating for 1 
hour allowed us to obtain a good 74% yield, and given the much shorter 
reaction time these were chosen to be the ideal conditions. 
Ring closing through C-H oxygenation was attempted using either K2S2O8 or 
NH4S2O8 as persulfate source, with and without AgNO3 and with different 
solvent mixtures. The only condition yielding more than just traces of product 
was the K2S2O8/AgNO310% system in 1/1 H2O/CH3CN which lead to the 
desired cyclized product with a non-optimal 30% yield. No advantage was 
obtained with the use of microwave heating in this case since the yield 
remained lower even after more than 1 hour (a time exceeding the average 
MW-assisted reaction time). Scheme 7 illustrates the reaction mechanism as it 
was hypothesized by the authors of the paper were this reaction was first 
reported169. It is clear how AgNO3 plays a key role after being oxidized to Ag2+ 
by persulfate, acting as one electron acceptor and favoring the formation of the 
carboxy radical. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 7 Reaction mechanism for the C-H oxygenation of 20 to achieve the methyl O-
protected UM6 21a 
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The only step that needed optimization in route B was the lactone ring formation 
through intramolecular Heck coupling. A rapid screening (table 5) revealed that 
regardless of the changes made to the system the reactivity was intrinsically 
lower than the Suzuki reaction in route A, never exceeding 35%. 
 
 
 
 
 
 
 
 
After careful consideration of several aspects, the route that was chosen as the 
most convenient was route A. In fact, despite the low yield in the C-H 
oxygenation step, it was judged that the fast reaction time obtained in the 
Suzuki step and the promising variability of future analogs brought by the use of 
boronic acids as building blocks would widely justify the choice of this route as 
by far the best one to obtain UM6 and its analogs. 
 
 
 
 
 
 
 
 
The final optimized synthesis is reported in scheme 8 and in addition to the 
steps already described it features an initial NBS-mediated bromination, the 
hydrolysis of 25a by KOH and the final deprotection using BBr3 which leads to 
Catalyst Base Solvent Yield  
Pd(OAc)2/PPh3 
1/4 
NaOAc DMF 35% 
Pd(OAc)2/PPh3 
1/4 
NaOAc DMA 9% 
Pd(PPh3)2Cl2 NaOPiv DMA 14% 
Table 5 Screening of reaction conditions for the 
intramolecular Heck coupling (route B) 
Scheme 8 Optimized synthesis of UM6 
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UM6 in an overall of 5 steps starting from commercially available compound 
22a. Key to the development of the other structural analogs of GF (17, 18 and 
19) was compound 25a. This molecule is central in the synthesis of UM6 and 
can be obtained fast and in good yield, and it played the role of a nodal 
commodity being incorporated into the synthesis of all the other compounds, 
therefore building a divergent and versatile route to up to 4 different structures 
all arising from one starting material. 
 
 
 
 
 
 
 
 
Phenanthrene derivative 19 was initially planned to be obtained through 
photocyclization of the corresponding stilbene170 (a standard approach to this 
kind of structures), but following the optimization of UM6 synthesis 25a was 
identified as a suitable precursor to an alternative bismuth-catalyzed synthesis 
of phenanthrenes, leading to the desired arylvinyl intermediate in only 3 
steps171.  
The synthesis of 19 is reported in scheme 9. After obtaining 25a the compound 
is converted to the corresponding aldehyde 26 and reacted in a Wittig fashion 
with (methoxymethyl)triphenylphosphonium chloride to afford the corresponding 
arylvinyl methyl ether 27. Bismuth-catalyzed cyclization-aromatization leads 
almost instantaneously to the protected phenanthrene 28 which is finally 
deprotected to obtain 19. 
The open analog 18 can be obtained by hydrolysis of 25a leading to the 
carboxilic acid 20 that is in turn deprotected by BBr3. The benzochromene 
Scheme 9 Synthesis of the phenanthrene-based analog 19 
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derivative 17 can be obtained after NaBH4/BF3·Et2O-mediated reduction of 
UM6. The synthesis of this compound has not yet been completed. 
The complete divergent approach to the synthesis of the 4 novel analogs of GF 
15, 17, 18 and 19 is reported in an overview scheme on page 62. It is possible 
to appreciate the central role of 25a in the system, placed in a nodal position at 
the intersection between 3 synthetic routes. 
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Scheme 10 Overview of the 
divergent synthesis of 15, 17, 18 and 
19 through the crucial intermediate 
25a. 
NB: compound 17 has not been 
obtained yet 
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Norbergenin (16) was the fifth product to be obtained for the initial screening, 
and the process for its synthesis was independent from the compounds 
described above. It is in fact possible to obtain norbergenin through its 
monomethylated analog bergenin (29), extracted from Bergenia and 
commercially available.  
The synthesis is a 3-step demethylation172, which is required due to the labile 
nature of 29 under dealkylation conditions with Lewis acids like BCl3 or BBr3. 
As reported in scheme 11, 29 is peracetylated using Ac2O and pyridine, and 
subsequently treated with BCl3 to remove the single methyl ether present on the 
molecule. Norbergenin is eventually obtained by acetyl group removal by 
aqueous K2CO3. 
 
 
 
 
Once the synthesis of candidate compounds 15, 16 and 19 was completed, 
they were assessed for biological activity in order to rank their similarity to 
galloflavin as LDH-A inhibitors. Before the results are reported it is important to 
mention that all molecules synthesized in this stage are soluble in DMSO, 
methanol and water and are stable at room temperature, therefore meeting the 
first requirements that these compounds needed to have to be considered as 
potential analogs of GF.   
The first assay carried out was aimed at establishing the ability of the 
compounds to inhibit isolated human LDH-A measuring NADH oxidation. 
Compounds 15 and 19, in which the tricyclic core is represented respectively by 
benzochromenone and phenanthrene maintained a comparable activity to the 
parent compound GF showing an IC50 of 77 and 62 μM respectively. 
Norbergenin shows no affinity to the enzyme, giving a result which was not 
entirely unexpected given its lower structural similarity to GF compared to the 
other compounds. 
Scheme 11 Synthesis of norbergenin from bergenin 
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Considering the ability of 15 and 19 to inhibit human LDH-A, we investigated 
their activity on lactic acid production and cell proliferation on Raji cells (see 
table 6 on page 66). Both compounds exert a marked effect on lactate 
production in cells at concentrations comparable to the ones inhibiting purified 
LDH-A (IC50 of 37 and 72 μM respectively) thus showing a good capacity of cell 
penetration. Moreover, 15 inhibited cell growth with an IC50 of 25 µM, whereas 
compound 19 at concentration of 25 µM inhibited completely the cell 
proliferation (100%), suggesting a mechanism of action related to different 
targets than LDH-A. 
In view of these encouraging results new analogs based on UM6 were designed 
to explore the SAR of this class of compounds. In particular, we wanted to 
evaluate the role of the number and position of the OH groups on the scaffold 
and the influence of changes in the lipophilicity of the molecules. 
To this purpose, through the previously established synthetic strategy three new 
analogs were prepared, demonstrating the versatility and modularity of the 
route. In figure 19 and scheme 12 the obtained compounds and synthetic 
intermediates are shown. 
 
 
 
 
Compound 33 is another member of the urolithins, urolithin M7 (UM7), the 
synthesis of which is already reported in the literature168. 32 and 33 bear three 
OH groups, one less than UM6, in different relative positions. Compound 34 is a 
3-phenyl analog of 32 synthesized with the aim of exploring the lipophilicity on 
that portion.  
Figure 19 The new compounds obtained to explore the SAR of GF and its analog UM6 
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Despite being still preliminary and incomplete, the results for these analogs 
confirm the validity of the UM6 structure and give some first hints on the 
functions of its hydrogen bond donors (a complete summary of the biological 
data is reported in table 6, 34 is not reported because insoluble). It is possible 
to observe how compound 33 (UM7) shows an increased ability to interact with 
the binding site (IC50 42 μM) despite lacking the characteristic gallic acid motif 
found in both GF and UM6. This motif nevertheless proofs to be necessary to 
retain activity on cell, since UM7 is surprisingly not active in reducing cell lactate 
or cell proliferation. As expected, 32 has a slightly lower activity on the enzyme, 
together with an even more marked loss of activity in cellular environment, thus 
suggesting the importance of a hydrogen bond donor on the 3-position. 
 
 
 
 
 
 
 
Scheme 12 The new compounds obtained to explore the SAR of GF and its analog UM6 
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Table 6 Activity of GF analogues 15-16, 19, 32-33 on purified human LDH-A 
and on lactic acid production and cell proliferation on Raji cells.  
 
aAll points were tested in triplicate with error bars indicating the standard 
deviations. bNot active. cNot determined. dThe compound shows 100% inhibition 
at 25 μM therefore suggesting an action based on different mechanisms 
involving not only LDH-A as a target. 
 
 
Compound 
hLDH-A 
IC50 (µM)a 
In-cells lactate 
production 
IC50 (µM)a 
 Cell 
proliferation 
IC50 (µM)a 
GF 
 
 
 
70 ± 10  62 ± 5  33 ± 4  
15 
(UM6) 
 
 
 
77 ± 10  36 ± 3  25 ± 2 
16 
 
n.a.b n.d.c n.d.c 
19 
 
 
 
62 ± 2  72 ± 15  < 25d  
32 
 
 
 
83 ± 5  175 ± 30  
 
62 ± 10  
 
33 
(UM7) 
 
 
 
42 ± 6  n.a.b n.a.b 
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3.3 Conclusion 
With the aim of gaining a better insight to the SAR of galloflavin, a series of 
analogs with high structural similarity to the original compound were designed 
and synthesized. A new synthetic strategy to obtain urolithins has been devised, 
together with the first reported synthesis of urolithin M6. The same strategy 
gave access to an overall of four compounds in a versatile route diverging from 
the same common precursor. Urolithin M6 reproduced in a satisfactory manner 
the inhibitory activity of GF on human LDH-A and will serve as a starting point 
for a further exploration. Preliminary information has been collected through the 
synthesis of a small number of analogs and more compounds will be available 
in the near future to better understand the influence of structural modifications 
on the activity of these new inhibitors. 
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3.4 Experimental section 
3.4.1 General methods 
Reaction progress was monitored by TLC on pre-coated silica gel plates 
(Kieselgel 60 F254, Merck) and visualized by UV254 light. Flash column 
chromatography was performed on silica gel (particle size 40-63 μM, Merck) or 
C18-reversed phase fully endcapped silica gel (particle size 40-63 μM, Sigma-
Aldrich). If required, solvents were distilled prior to use. All reagents were 
obtained from commercial sources and used without further purification. When 
stated, reactions were carried out under an inert atmosphere. Reactions 
involving microwave irradiation were performed using a microwave synthesis 
system (CEM Discover® SP, 2.45 GHz, maximum power 300 W), equipped with 
infrared temperature measurement. Compounds were named relying on the 
naming algorithm developed by CambridgeSoft Corporation and used in Chem-
BioDraw Ultra 15.0. 1H-NMR and 13C-NMR spectra were recorded on Varian 
Gemini at 400 MHz and 100 MHz respectively. Chemical shifts (δH) are reported 
relative to TMS as internal standard. 
 
3.4.2 Synthetic procedures 
Methyl 2-bromo-3,4,5-trimethoxybenzoate 23a 
Methyl 3,4,5-trimethoxybenzoate 22a (10.200 g, 45.087 mmol, 1.0 
eq.) was dissolved in CH3CN (400 mL). The mixture was cooled to 
0°C and NBS (8.827 g, 49.596 mmol, 1.1 eq.) was added portionwise. The 
reaction was let warm up to room temperature and stirred for 4 hours. After TLC 
showed completion Na2S2O3 2M was added. After stirring for 5 minutes CH3CN 
was evaporated in vacuum and the mixture extracted 3 times with EtOAc. The 
combined organic phases were dried over anhydrous Na2SO4, and the solvent 
evaporated in vacuum. The crude product was purified via silica gel column 
chromatography (Petroleum ether/EtOAc 85/15 ratio) to obtain the pure product 
as a colourless viscous liquid which solidifies after standing overnight (yield 
95%). 1H NMR (400 MHz, CDCl3) δ 7.15 (s, 1H), 3.93 (s, 6H), 3.89 (s, 6H) ppm. 
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Methyl 4,4',5,6-tetramethoxy-[1,1'-biphenyl]-2-carboxylate 25a 
Methyl 2-bromo-3,4,5-trimethoxybenzoate 23a (800 mg, 2.622 
mmol, 1.0 eq.) was dissolved in 1,2-dimethoxyethane (90 ml, N.B. more 
concentrated reactions might lead to extensive formation of side products and 
deactivation of the catalyst) inside a pressure tube and 4-methoxyphenylboronic 
acid 24a (598 mg, 3.933 mmol, 1.5 eq.), K2PO4 (1109 mg, 5.244 mmol, 2.0 eq.) 
and tetrakis(triphenylphosphine)palladium (303 mg, 0.262 mmol, 0.1 eq.) were 
added. The tube was sealed, the reaction was heated to 120°C and stirred for 
24h. The mixture was transferred to a round bottom flask and the solvent 
removed in vacuum. The crude product was purified via silica gel column 
chromatography (Petroleum ether/EtOAc 90/10 ratio) to obtain the pure product 
as a colourless viscous liquid (yield 74%). 1H NMR (400 MHz, CDCl3) δ 7.17 (s, 
1H), 7.14 (d, J = 8.7 Hz, 2H), 6.90 (d, J = 8.7 Hz, 2H), 3.93 (s, 3H), 3.91 (s, 3H), 
3.83 (s, 3H), 3.56 (s, 3H), 3.54 (s, 3H) ppm. 
 
3,8,9,10-tetramethoxy-6H-benzo[c]chromen-6-one 21a 
Methyl 4,4',5,6-tetramethoxy-[1,1'-biphenyl]-2-carboxylate 25a 
(1590 mg, 4.784 mmol) was treated with 25 mL of a 1/1 mixture of 
4M NaOH and EtOH at 60°C. After TLC showed absence of starting material 
the reaction was treated with 37% HCl until acidic pH, brine was added and the 
mixture was extracted 3 times with EtOAc. The combined organic phases were 
dried over anhydrous Na2SO4, and the solvent evaporated in vacuum. The 
crude product, used without further purification, was added 50 mL of a 1/1 
H2O/CH3CN mixture. K2S2O8 (3880 mg, 14.353 mmol, 3.0 eq.) and AgNO3 (81 
mg, 0.478 mmol, 0.1 eq.) were added and the reaction was stirred at 60°C for 
48h. CH3CN was evaporated in vacuum and the mixture extracted 3 times with 
EtOAc. The combined organic phases were dried over anhydrous Na2SO4, and 
the solvent evaporated in vacuum. The crude product was purified via silica gel 
column chromatography (Petroleum ether/EtOAc 85/15 ratio) to obtain the pure 
product as an off white solid (yield 30%). 1H NMR (400 MHz, CDCl3) δ 8.74 (d, J 
= 9.0 Hz, 1H), 7.72 (s, 1H), 6.90 (dd, J = 9.0, 2.7 Hz, 1H), 6.87 (d, J = 2.7 Hz, 
1H), 4.04 (s, 3H), 3.99 (s, 3H), 3.96 (s, 3H), 3.88 (s, 3H) ppm. 
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3,8,9,10-tetrahydroxy-6H-benzo[c]chromen-6-one 15 (Urolithin 
M6) 
3,8,9,10-tetramethoxy-6H-benzo[c]chromen-6-one 21a (105 mg, 
0.332 mmol, 1.0 eq.) was dissolved in dry DCM (10 mL) in a flame dried flask 
and the mixture was cooled to -78°C. BBr3 1.0M in DCM (2.656 mL, 2.656 
mmol, 8 eq. [2 eq. per methoxy group]) was slowly added dropwise. The 
reaction was let warm up to room temperature and stirred for 24 hours. 5 mL of 
MeOH were added and the solvent was removed in vacuum. The crude product 
was purified via C18 silica gel reverse phase column chromatography 
(H2O/MeOH/HCOOH elution gradient from a 70/30/0.1 ratio to a 30/70/0.1 ratio) 
to obtain the product in a mixture with a minor dark impurity not detectable 
using NMR, which was removed washing the product with small amounts of 
MeOH, yielding the pure compound as a grey solid (yield 58%). 1H NMR (400 
MHz, DMSO-d6) δ 10.19 (s, 1H), 9.96 (s, 1H), 9.91 (s, 1H), 9.49 (s, 1H), 8.80 
(d, J = 8.9 Hz, 1H), 7.28 (s, 1H), 6.75 (d, J = 8.9 Hz, 1H), 6.67 (s, 1H) ppm; 13C 
NMR (400 MHz, DMSO-d6) δ 160.74, 157.30, 150.68, 145.27, 142.52, 140.30, 
128.02, 116.00, 112.01, 110.63, 110.23, 106.82, 102.57 ppm; MS (ES): m/z 261 
[M + H]+, 283 [M + Na]+, Anal. Calcd. for C13H8O6 (%): C, 60.01; H, 3.10; O, 
36.89. Found (%): C, 60.03; H, 3.12; O, 36.90. 
 
Methyl 2-bromo-3,5-dimethoxybenzoate 23b 
The compound was obtained as a colourless viscous liquid (yield 
88%), with the same procedure used for 23a, using methyl-3,5-
dimethoxybenzoate 22b as starting material. 1H NMR (400 MHz, CDCl3) δ 6.79 
(d, J = 2.8 Hz, 1H), 6.57 (d, J = 2.8 Hz, 1H), 3.92 (s, 3H), 3.87 (s, 3H), 3.81 (s, 
3H) ppm. 
 
Methyl 4,4',6-trimethoxy-[1,1'-biphenyl]-2-carboxylate 25b 
The compound was obtained as an off white solid (yield 85%), 
with the same procedure used for 25a, using methyl 2-bromo-3,5-
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dimethoxybenzoate 23b as starting material. 1H NMR (400 MHz, CDCl3) δ 7.17 
(d, J = 8.7 Hz, 2H), 6.92 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 2.4 Hz, 1H), 6.65 (d, J 
= 2.4 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.78 (s, 3H), 3.57 (s, 3H) ppm. 
  
3,8,10-trimethoxy-6H-benzo[c]chromen-6-one 21b 
The compound was obtained as a white solid (yield 43%), with the 
same procedure used for 21a, using methyl 4,4',6-trimethoxy-
[1,1'-biphenyl]-2-carboxylate 25b as starting material. 1H NMR (400 MHz, 
CDCl3) δ 8.75 (dd, J = 7.7, 2.4 Hz, 1H), 7.48 (d, J = 2.5 Hz, 1H), 6.88 (d, J = 2.5 
Hz, 1H), 6.87-6.84 (m, 2H), 4.02 (s, 3H), 3.92 (s, 3H), 3.87 (s, 3H) ppm. 
 
3,8,10-trihydroxy-6H-benzo[c]chromen-6-one 33 (Urolithin M7) 
The compound was obtained as a light yellow solid (yield 80%), 
with the same procedure used for 15, using 3,8,10-trimethoxy-
6H-benzo[c]chromen-6-one 21b as starting material. 1H NMR (400 MHz, 
DMSO-d6) δ 10.73 (s, 1H), 9.98 (s, 1H), 9.95 (s, 1H), 8.76 (d, J = 8.9 Hz, 1H), 
7.14 (d, J = 1.6 Hz, 1H), 6.87 (d, J = 1.6 Hz, 1H), 6.77 (d, J = 8.9 Hz, 1H), 6.71 
(s, 1H) ppm; 13C NMR (400 MHz, DMSO-d6) δ 160.78, 157.28, 156.99, 156.06, 
150.23, 128.01, 121.64, 114.78, 112.36, 109.93, 109.63, 106.01, 102.65 ppm; 
MS (ES): m/z 245 [M + H]+, 267 [M + Na]+, Anal. Calcd. for C13H8O5 (%): C, 
63.94; H, 3.30; O, 32.76. Found (%): C, 63.92; H, 3.28; O, 32.76. 
 
Methyl 4,5,6-trimethoxy-[1,1'-biphenyl]-2-carboxylate 25c 
The compound was obtained as a colourless viscous liquid which 
crystallizes after standing overnight (yield 82%), with the same 
procedure used for 25a, using methyl 2-bromo-3,4,5-trimethoxybenzoate 23a 
and phenylboronic acid 24b as starting materials. 1H NMR (400 MHz, CDCl3) δ 
7.40 – 7.29 (m, 3H), 7.23 (d, J = 8.3 Hz, 2H), 7.22 (s, 1H), 3.95 (s, 3H), 3.92 (s, 
3H), 3.56 (s, 3H), 3.52 (s, 3H) ppm. 
 
8,9,10-trimethoxy-6H-benzo[c]chromen-6-one 21c 
The compound was obtained as an off white solid (yield 60%), with 
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the same procedure used for 21a, using methyl 4,5,6-trimethoxy-[1,1'-biphenyl]-
2-carboxylate 25c as starting material. 1H NMR (400 MHz, CDCl3) δ 8.85 (d, J = 
8.2 Hz, 1H), 7.77 (s, 1H), 7.44 (t, J = 7.7 Hz, 1H), 7.36 (d, J = 8.2 Hz, 1H), 7.32 
(t, J = 7.7 Hz, 1H), 4.04 (s, 3H), 4.00 (s, 3H), 3.99 (s, 3H) ppm. 
 
8,9,10-trihydroxy-6H-benzo[c]chromen-6-one 32 
The compound was obtained as an off white solid (yield 87%), with 
the same procedure used for 15, using 8,9,10-trimethoxy-6H-
benzo[c]chromen-6-one 21c as starting material. 1H NMR (400 MHz, DMSO-d6) 
δ 10.40 (s, 1H), 10.03 (s, 1H), 9.74 (s, 1H), 9.01 (d, J = 7.7 Hz, 1H), 7.39 (dd, J 
= 7.7, 6.8 Hz, 1H), 7.36 (s, 1H), 7.34 – 7.28 (m, 2H) ppm; 13C NMR (400 MHz, 
DMSO-d6) δ 160.42, 149.28, 146.38, 143.78, 140.25, 127.83, 126.87, 124.02, 
118.59, 116.46, 114.78, 112.11, 107.16 ppm; MS (ES): m/z 245 [M + H]+, 267 
[M + Na]+, Anal. Calcd. for C13H8O5 (%):C, 63.94; H, 3.30; O, 32.76. Found 
(%):C, 63.96; H, 3.31; O, 32.77. 
 
Methyl 4,5,6-trimethoxy-[1,1':4',1''-terphenyl]-2-carboxylate 
25d 
The compound was obtained as a yellow viscous liquid (yield 
70%), with the same procedure used for 25a, using methyl 2-
bromo-3,4,5-trimethoxybenzoate 23a and 4-biphenylboronic 24c acid as 
starting materials. 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 7.5 Hz, 2H), 7.64 
(d, J = 8.1 Hz, 2H), 7.46 (t, J = 7.5 Hz, 2H), 7.36 (t, J = 7.5 Hz, 1H), 7.32 (d, J = 
8.1 Hz, 2H), 7.25 (s, 1H), 3.98 (s, 3H), 3.95 (s, 3H), 3.62 (s, 3H), 3.57 (s, 3H) 
ppm. 
 
8,9,10-trimethoxy-3-phenyl-6H-benzo[c]chromen-6-one 21d 
The compound was obtained as a light yellow solid (yield 
33%), with the same procedure used for 21a, using methyl 
4,5,6-trimethoxy-[1,1':4',1''-terphenyl]-2-carboxylate 25d as starting material. 1H 
NMR (400 MHz, CDCl3) δ 8.90 (d, J = 8.0 Hz, 1H), 7.78 (s, 1H), 7.66 (d, J = 7.6 
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Hz, 2H), 7.62 (d, J = 8.0 Hz, 1H), 7.44 (t, J = 7.6 Hz, 2H), 7.36 (d, J = 8.0 Hz, 
1H), 7.33 (t, J = 8.0 Hz, 1H), 4.06 (s, 3H), 4.02 (s, 3H), 4.01 (s, 3H) ppm. 
 
8,9,10-trihydroxy-3-phenyl-6H-benzo[c]chromen-6-one 34 
The compound was obtained as a beige solid (yield 62%), with 
the same procedure used for 15, using 8,9,10-trimethoxy-3-
phenyl-6H-benzo[c]chromen-6-one 21d as starting material. 1H NMR (CD3OD) 
δ 9.15 (d, J = 8.5 Hz, 1H), 7.71 (d, J =7.5, 2H), 7.59 (dd, J = 8.5, 1.9 Hz, 1H), 
7.56 (d, J = 1.9 Hz, 1H), 7.47 (t, J = 7.5 Hz, 2H), 7.44 (s, 1H), 7.37 (t, J = 7.5 
Hz, 1H) ppm; 13C NMR (400 MHz, DMSO-d6) δ 160.50, 149.84, 146.49, 143.79, 
140.28, 139.35, 138.60, 129.02, 127.96, 127.92, 127.38, 126.63, 122.22, 
119.50, 117.73, 114.68, 114.02, 112.03, 107.27 ppm; MS (ES): m/z 321 [M + 
H]+, 343 [M + Na]+, Anal. Calcd. for C19H12O5 (%):C, 71.25; H, 3.78; O, 24.98. 
Found (%):C, 71.27; H, 3.80; O, 24.99. 
 
(4,4',5,6-tetramethoxy-[1,1'-biphenyl]-2-yl)methanol 25r 
Methyl 4,4',5,6-tetramethoxy-[1,1'-biphenyl]-2-carboxylate 25a 
(650 mg, 1.956 mmol, 1.0 eq.) was dissolved in dry CH2Cl2 (8 
mL) and the mixture was cooled to 0°C. DIBAL 1.0 M in hexane (8.2 mL, 8.214 
mmol, 4,2 eq.) was added dropwise. The reaction was then warmed to room 
temperature and stirred for 3 hours. H2O and CH2Cl2 were added and the 
mixture was filtered to remove the precipitate. The phases were separated and 
the aqueous phase was extracted 2 times with CH2Cl2. The combined organic 
phases were dried over anhydrous Na2SO4, and the solvent evaporated in 
vacuum. The crude product was purified via silica gel column chromatography 
(Petroleum ether/EtOAc 80/20 ratio) to obtain the pure product as a light brown 
viscous liquid (yield 73%). 1H NMR (400 MHz, CDCl3) δ 7.18 (d, J = 8.5 Hz, 
2H), 6.96 (d, J = 8.5 Hz, 2H), 6.89 (s, 1H), 4.42 (d, J = 5.7 Hz, 2H), 3.92 (s, 3H), 
3.90 (s, 3H), 3.85 (s, 3H), 3.60 (s, 3H) ppm. 
 
4,4',5,6-tetramethoxy-[1,1'-biphenyl]-2-carbaldehyde 26 
(4,4',5,6-tetramethoxy-[1,1'-biphenyl]-2-yl)methanol 25r (359 mg, 
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1.180 mmol, 1.0 eq.) was dissolved CH2Cl2 (10 mL), PCC (381 mg, 1.769 
mmol, 1.5 eq.) was added and the reaction was stirred at room temperature for 
4 hours. The reaction was filtered on celite and the solvent evaporated to yield 
the product as a pale yellow deliquescent solid which was used without further 
purification (yield 75%). 1H NMR (400 MHz, CDCl3) δ 9.68 (s, 1H), 7.35 (s, 1H), 
7.25 (d, J = 8.5 Hz, 2H), 6.98 (d, J = 8.5 Hz, 2H), 4.00 (s, 3H), 3.95 (s, 3H), 3.87 
(s, 3H), 3.59 (s, 3H) ppm. 
 
2,3,4,4'-tetramethoxy-6-(2-methoxyvinyl)-1,1'-biphenyl 27 
(Methoxymethyl)triphenylphosphonium chloride (352 mg, 1.027 
mmol, 1.5 eq.) was dissolved in dry THF (3 mL) and the mixture 
was cooled to 0°C under inert atmosphere. LiHMDS 1.0 M in THF (1.370 mL, 
1.370 mmol, 2 eq.) was slowly added and the reaction was stirred for 10 
minutes. 4,4',5,6-tetramethoxy-[1,1'-biphenyl]-2-carbaldehyde 26 (207 mg, 
0.685 mmol, 1.0 eq.) was dissolved in dry THF (4 mL) in a separate flask and 
the solution was added slowly to the reaction mixture. The reaction was warmed 
to room temperature and stirred for 1 hour. H2O was added and the mixture was 
extracted 3 times with EtOAc. The combined organic phases were dried over 
anhydrous Na2SO4, and the solvent evaporated in vacuum. The crude product 
was purified via silica gel column chromatography (Petroleum ether/EtOAc 
90/10 ratio) to obtain the pure product as a colourless viscous liquid (yield 56%, 
60/40 mixture of E/Z isomers) 1H NMR (400 MHz, CDCl3) δ 7.51 (s, 0.40X1H, Z-
isomer), 7.16 (d, J = 8.3 Hz, 2H), 6.92 (d, J = 8.3 Hz, 2H), 6.79 (d, J = 12.9 Hz, 
0.60X1H, E-isomer), 6.68 (s, 0.60X1H, E-isomer), 5.95 (d, J = 7.2 Hz, 0.40X1H, 
Z-isomer), 5.50 (d, J = 12.9 Hz, 0.60X1H, E-isomer), 4.91 (d, J = 7.2 Hz, 
0.40X1H, Z-isomer), 3.89 (s, 3H), 3.87 (s, 3H), 3.84 (s, 3H), 3.73 (s, 0.40X3H, 
Z-isomer), 3.56 (s, 0.60X3H, E-isomer), 3.54 (s, 0.40X3H, Z-isomer), 3.46 (s, 
0.60X3H, E-isomer) ppm. 
 
2,3,4,7-tetramethoxyphenanthrene 28 
2,3,4,4'-tetramethoxy-6-(2-methoxyvinyl)-1,1'-biphenyl 27 (127 
mg, 0.384 mmol, 1.0 eq.) was dissolved in 1,2-dichloroethane (3 
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mL) under nitrogen atmosphere. Bismuth(III) trifluoromethanesulfonate (17 mg, 
0.019 mmol, 0.05 eq.) was added and the reaction was stirred at room 
temperature for 30 minutes. After TLC showed full conversion the solvent was 
evaporated. The crude was dissolved in CH2Cl2 and filtered on a sintered glass 
funnel equipped with a 1.5 cm thick layer of silica, washing several times to 
assure complete elution. The pure compound was obtained as a white solid 
(yield 65%). 1H NMR (400 MHz, CDCl3) δ 9.42 (d, J = 9.2 Hz, 1H), 7.59 (s, 2H), 
7.29 – 7.22 (m, 2H), 7.08 (s, 1H), 4.04 (s, 3H), 4.02 (s, 3H), 4.01 (s, 3H), 3.96 
(s, 3H) ppm. 
 
Phenanthrene-2,3,4,7-tetraol 19 
The compound was obtained as a gray solid (yield 86%), with 
the same procedure used for 15, using 2,3,4,7-
tetramethoxyphenanthrene 28 as starting material. 1H NMR (400 MHz, DMSO-
d6) δ 9.66 (s, 1H), 9.43 (d, J = 9.2 Hz, 1H), 9.42 (s, 1H), 8.94 (s, 1H), 8.87 (s, 
1H), 7.40 (d, J = 8.8 Hz, 1H), 7.33 (d, J = 8.8 Hz, 1H), 7.09 (d, J = 2.5 Hz, 1H), 
7.02 (dd, J = 9.2, 2.5 Hz, 1H), 6.79 (s, 1H) ppm; 13C NMR (400 MHz, DMSO-d6) 
δ 153.99, 144.84, 143.25, 132.77, 132.73, 128.63, 126.86, 125.30, 123.83, 
123.52, 115.64, 113.60, 110.92, 103.81 ppm; MS (ES): m/z 243 [M + H]+, 265 
[M + Na]+, Anal. Calcd. for C14H10O4 (%): C, 69.42; H, 4.16; O, 26.42. Found 
(%): C, 69.43; H, 4.18; O, 26.42. 
 
Norbergenin 16 
Bergenin 29 (500 mg, 1.523 mmol, 1.0 eq.) was dissolved in 
pyridine (2 mL) and Ac2O (2 mL) and the reaction was stirred at 
room temperature for 24 hours. Water was added and the 
mixture was extracted 3 times with EtOAc. The combined organic phases were 
dried over anhydrous Na2SO4, and the solvent evaporated in vacuum and dried 
in high vacuum. The crude (600 mg, 1.226 mmol, 1.0 eq.) was dissolved in 
CH2Cl2 (15 mL) and then BCl3 1.0 M in CH2Cl2 (7.354 mL, 7.354 mmol, 5.0 eq. ) 
was added at 0°C and stirred for 1 h. After stirring at room temperature for 24 h, 
the reaction mixture was poured into ice-water. The organic solvent was 
removed in vacuum, and then the water layer was added to 10% K2CO3 
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solution, and stirred for 1 h. The reaction mixture was acidified with 2.0 M HCl, 
and then the water layer absorbed with DIAION HP-20 resin. The fraction eluted 
with MeOH was concentrated in vacuum, and the residue was purified by 
recrystallization to afford the product as a white solid (yield 78% over the 3 
steps). 1H NMR (400 MHz, CD3OD) δ 7.09 (s, 1H), 4.94 (d, J = 10.5 Hz, 1H), 
4.04 (t, J = 9.9 Hz, 2H), 3.81 (t, J = 9.0 Hz, 1H), 3.76 – 3.61 (m, 2H), 3.43 (t, J = 
9.0 Hz, 1H) ppm; 13C NMR (400 MHz, CD3OD) δ 166.39, 147.25, 143.64, 
141.17, 117.34, 114.28, 110.98, 82.97, 81.40, 75.64, 74.35, 71.95, 62.71 ppm; 
MS (ES): m/z 315 [M + H]+, 337 [M + Na]+, Anal. Calcd. for C13H14O9 (%): C, 
49.69; H, 4.49; O, 45.82. Found (%): C, 49.70; H, 4.51; O, 45.83. 
 
4,4',5,6-tetrahydroxy-[1,1'-biphenyl]-2-carboxylic acid 18 
The compound was obtained as a gray solid (yield 86%), with 
the same procedure used for 15, using methyl 4,4',5,6-
tetramethoxy-[1,1'-biphenyl]-2-carboxylic acid 20 as starting material. 1H NMR 
(400 MHz, DMSO-d6) δ 11.76 (s, 1H), 9.34 (s, 1H), 9.14 (s, 1H), 8.91 (s, 1H), 
8.02 (s, 1H), 6.91 (d, J = 8.4 Hz, 1H), 6.77 (s, 1H), 6.66 (d, J = 8.4 Hz, 1H) ppm; 
13C NMR (400 MHz, DMSO-d6) δ 169.21, 155.57, 149.73, 143.84, 143.69, 
135.80, 130.91, 128.21, 122.84, 121.65, 115.65, 114.09, 108.24 ppm; MS (ES): 
m/z 263 [M + H]+, 285 [M + Na]+, Anal. Calcd. for C13H10O6 (%): C, 59.55; H, 
3.84; O, 36.61. Found (%): C, 59.54; H, 3.86; O, 36.62. 
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CHAPTER 4 
 
Towards the total synthesis of rakicidin A 
 
 
4.1 Introduction 
Tumor hypoxia and cancer stem cells (CSCs) are crucial factors contributing to 
chemo- and radioresistance in cancer (see paragraph 1.3). They are correlated 
with poor prognosis and aggressive phenotype because of their tumor-initiating 
potential, favoring both the primary onset and the metastatic phase68,173. 
rakicidin A (RakA) (figure 20 compound 36) is a natural macrocyclic 
depsipeptide produced by Micromonospora sp. bacteria, isolated from a sample 
of Indian soil and first reported in 1995174 together with is closely related analog 
rakicidin B (RakB) (figure 20 compound 37).  
 
 
 
 
 
 
The relevance of RakA was highlighted since the first days of its discovery 
because of its nanomolar hypoxia-selective cytotoxicity towards a variety of 
cancer cell lines174,175 (with the strongest effect on human colorectal 
adenocarcinoma and pancreas tumor) and its promising activity against 
imatinib-resistant CSCs of chronic myelogenous leukemia176. Notably, RakA 
does not perturb the transcriptional activity of HIF-1 and its cytotoxicity under 
normoxic conditions is not affected by the presence of antioxidants175 therefore 
excluding the option of a simple bioreductive activation mechanism. 
The actual mechanism through which RakA exerts its effect is still unknown and 
currently under investigation. A key to its activity might be found in the highly 
peculiar (E)-4-amido-2,4-pentadienoate (APD) portion, which RakA shares with 
Figure 20 Rakicidin A (36) and Rakicidin B (37), macrocyclic depsipeptides isolated from Micromonospora 
sp. 
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a few other known natural compounds, such as vinylamycin and microtermolide 
A177,178. Using a model macrocyclic system, it has been recently demonstrated 
that this functionality can react as an electrophilic site in a 1,6 Michael fashion 
with thiol nucleophiles, including cysteine residues incased in BSA-derived 
tryptic peptides179. Further data will be described later on in this chapter to 
demonstrate how, most likely, the molecule needs this electrophilic portion to 
retain its activity, but despite this the biological molecular target (or targets) is 
still unknown. 
Surrounding the APD portion, the complex architecture characterizing RakA is 
completed by a β-hydroxy fatty acid side chain and two non-proteinogenic 
amino acids: sarcosine and β-hydroxyasparagine (β-HOAsn). Unexpectedly, the 
fatty acid portion is also crucial for the high activity and selectivity of RakA, 
since its analog RakB shows a significantly lower cytotoxicity towards cancer 
cells174, despite differing by one single carbon atom in the length of the alkyl 
chain (figure 20). 
The configuration of the 5 stereogenic centers has been uncertain until 2014, 
when Chen and co-workers claimed the synthesis of a compound that matched 
the spectroscopic data reported for the natural product, assigning the 
stereochemistry as (2S,3S,14S,15S,16R)180. Shortly after this paper was 
published, Igarashi and co-workers paradoxically concluded the 
stereochemistry to be (2R,3R,14S,15S,16R) by direct degradation of the natural 
product and comparison with authentic standards181. The latter was later on 
found to arise from a practical mistake and was corrected and aligned with the 
(2S,3S,14S,15S,16R) configuration, therefore completing a characterization of 
the compound which can be agreed upon beyond any reasonable doubt.  
At the onset of the project for the total synthesis of RakA in T.B. Poulsen’s lab, 
the stereochemistry was still unknown and the synthetic effort was originally 
directed towards several candidate isomers, with the most promising being the 
one that later one turned out to be ent-RakA (i.e. 2R,3R,14R,15R,16S). This 
configuration arose from a combination of NOE and computational 
conformational analysis of a previously developed model system of the 
macrocyclic ring182 as well as surveys of the literature. After the clarification of 
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the stereochemistry the strategy was adjusted and directed towards the total 
synthesis of the natural isomer.  
In the coral effort that was carried out to obtain this complex compound, I was 
involved in the optimization and adjustment of reaction conditions to obtain 
some of the precursors of the natural product as well precursors of ent-RakA 
and other non-natural epimers, that might play a future role in the investigation 
of the compound’s mechanism of action. In the next paragraph I will mostly 
describe my personal contribution, and I will conclude by shortly reporting the 
overall successful strategy that was completed and published shortly after the 
end of my visiting period. 
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4.2 Results and discussion 
With β-HOAsn being one of the four components of the molecular structure of 
RakA, we wanted to obtain access the four possible diasteroisomers of the 
compound. The precursor to β-HOAsn is β-hydroxyaspartic acid (β-HOAsp), 
which exists in the threo and erythro form. The threo form is commercial and is 
sold as a racemic mixture which can be resolved via a known procedure183. The 
erythro form had to be prepared and its synthesis184 is reported in scheme 13. 
 
 
 
 
 
 
Diethyl tartrate in the suitable optically pure diasteroisomer was treated with 
SOCl2 to obtain the intermediate cyclic sulfite 38 which was not isolated and 
was treated in-situ with NaN3 to yield the corresponding organic azide 39 with 
the correct configuration after inversion of the stereocenter. The compound was 
in turn reduced to the corresponding amine 40 and subsequently hydrolyzed to 
obtain the desired erythro (R,S)-β-HOAsp. 
The transformation of HOAsp to HOAsn was planned to belong to a later stage 
of the synthesis, after the incorporation of all the fragments and the formation of 
the macrocycle, so the next fragment prepared was the β-hydroxy fatty acid 
side chain. With no known stereochemistry at the time one of the first 
configurations tested was the (R,R,R). On scheme 14 the synthesis of 
precursor aldehyde 46 is shown. 
Scheme 13 Synthesis of erythro (R,S)-β-HOAsp 41 (the opposite enantiomer can be obtained with the 
same procedure starting from (+)-Diethyl L-tartrate) 
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Acid 42 was functionalized with Evans auxiliary (R)-4-Benzyl-2-oxazolidinone 
and α-methylated to obtain 44 as one diasteroisomer, which was then 
transformed to the corresponding chiral aldehyde 46 via a two-step reduction-
oxydation. This aldehyde served as a starting material for the next steps, aimed 
to obtain the fatty acid as its benzyl ester 53 via the process described in 
scheme 15, but it also proved crucial in the final strategy to the natural 
compound.  
At this stage the goal was to convert 46 to its correspondent allyl alcohol 48 in 
order to exploit the Sharpless reactivity of this functionality to build the next two 
stereocenters. The aldehyde was therefore reacted with ethyl 
(triphenylphosphoranylidene)acetate to obtain the Witting product 47 and DIBAL 
reduction afforded the desired allyl alcohol 48. The Sharpless epoxidation 
proved hard to optimize but after several attempts it was found that extremely 
dry conditions and a careful dosage of the equivalents as stated in scheme 15 
could lead to the epoxide 49 in high yield and a dr of 9:1 which was judged 
sufficient for our purposes, given that the pure isomer could be easily isolated 
by column chromatography and the conditions proved robust and suitable to 
gram-scale synthesis. 
Scheme 14 Synthesis of intermediate chiral aldehyde 46 
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Once the stereoinformation had been induced in the molecule it became easy to 
complete the triad by simply opening the epoxide ring with a copper-assisted 
nucleophilic methylation to obtain 50. Once this point was reached, the two-step 
oxidation and the benzyl ester formation proceeded smoothly to the desired 
product 53.  
A negative outcome was obtained with this procedure while working on the 
configuration corresponding to this fragment in ent-RakA (R,R,S), and several 
alternatives were considered. A highly selective Oppolzer aldol reaction185 using 
a superstoichiometric amount of TiCl4 on intermediate could be carried out to 
form the desired anti-syn-stereotriad as shown in 54, however, the reaction 
lacked in reproducibility and occasionally drastically reduced yields and 
diastereoselectivities were observed.  
 
 
 
Scheme 15 Synthesis of the benzyl protected β-hydroxy fatty acid side chain fragment 53 
Figure 21 Product of the Oppolzer aldol carrying the anti-syn triad and the chiral auxiliary 
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The β-HOAsp 41 was then merged with 53 to build the first half of the 
macrocycle. 
To this purpose 41 was Fmoc protected on the amine functionality and the α-
hydroxy acid was enclosed in a lactone ketal using 2,2-dimethoxypropane. This 
solution allowed for the simultaneous protection of two functionalities while at 
the same time granting a suitable reactivity in the future conversion of the acid 
into an amide. The free acid functionality of 56 was in turn esterified with the OH 
group of 53 under Steglich conditions to yield 57. 
At this point the synthetic strategy was planned to continue through formation of 
the APD fragment precursor 64 (scheme 17), in the form of the corresponding 
δ-thio-α,β-unsaturated amide (which would subsequently undergo thiol 
elimination to afford the pentadienoate functionality), followed by amide 
formation between the amine of 64 and the acid of 57 and subsequent 
macrocyclization. This hypothesis was never completed and the strategy was 
later changed to a different cyclization site. 
 
 
 
 
 
 
 
Scheme 16 Synthesis of fragment 57 carrying the lipid chain connected to the protetcted β-HOAsp 
Scheme 17 Synthesis of the precursor of the APD fragment 
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Compound 64 was obtained starting from sarcosine methylester, acylated with 
bromoacetyl bromide to obtain 59. The compound was transformed into the 
corresponding phosphonate and in turn converted to the allyl ester 62. This 
compound was merged with aldehyde 63186 in a Horner-Wadsworth-Emmons 
(HWE) reaction to obtain the desired α,β-unsaturated amide. 
 
 
 
 
 
 
After evaluating many alternative options for the aldol reaction, the analog of 57 
carrying the natural product configuration (67, scheme 18) was obtained 
through a proline-catalyzed cross-aldol reaction187 between propanal and 46 
which proceeded with high anti-selectivity yielding the desired anti-aldol-Felkin 
motif, thus constituting an efficient and reliable method for accessing hydroxy 
ester 66 after Pinnick oxidation and benzylation of the carboxylic acid. The 
typical isolated yields from the cross aldol reaction ranged from 30-40% 
following chromatographic isolation but a large part of unreacted starting 
material was recovered and re-reacted to increase the final yield.  
After several attempts, the option of carrying out the cyclization through amide 
formation between the APD unit precursor and the fatty acid was judged 
unfeasible, and the project required a thorough reprogramming of the synthetic 
strategy towards a more effective cyclization site. 
The total synthesis was successfully concluded thanks to the collaboration of 
other members of the group188 and the synthetic scheme for the last steps is 
reported as published in figure 22 (compound numbers in this figure refer to the 
article numeration system). The new strategy focused on a HWE-mediated 
cyclization thus building the APD portion as the last step. 
Scheme 18 Synthesis of the lipid chain/β-HOAsp fragment with the natural product configuration 
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The cyclization precursor was obtained by two efficient EDCI-mediated 
couplings resulting in the desired phosphonate in high yield. The 
macrocyclization sequence commenced with initial DMP-oxidation of the 
primary alcohol followed by exposure of the resulting aldehyde-phosphonate to 
TMEDA-Zn(OTf)2189 and trimethylamine, thus affording HWE reactivity. 
Deprotection of the lactone-ketal to the hydroxy acid could be carried out 
efficiently using aq. AcOH in THF and this crude material was directly subjected 
to a PyBOP-mediated coupling with ammonium-bicarbonate resulting in the 
corresponding hydroxy-amide. Dehydration to the sensitive APD-functionality 
could be achieved using a one-pot reaction employing N,N′-disuccinimidyl 
carbonate (DSC)190 at slightly elevated temperature. Final purification by HPLC 
and subsequent lyophilization delivered pure rakicidin A as a white powder. 
Figure 22 Construction of the linear precursor, cyclization and DSC-mediated dehyration to complete the 
total synthesis of RakA (compound numbers are reported as in the final publication) 
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Synthetic rakicidin A matched all spectroscopic data reported for the natural 
product. 
A biological evaluation of the compound was then conducted and the assay on 
the synthetic compound matched the promising activity of the natural isolate: 
RakA showed nanomolar inhibitory activity on cell growth of PANC-1 cells 
(GI50=36±1.4 nM) with a high Selectivity Index for inhibition under hypoxic vs. 
normoxic conditions (SI=9.8±1.0). It was furthermore demonstrated that RakA is 
not a proteasome inhibitor (as it may be suggested by structural similarity with 
the proteasome inhibitors of the syrbactin family191), by comparison with 
bortezomib activity under hypoxic conditions and by direct evaluation of the 
inhibition of the proteolytic activities of the proteasome. The actual mechanism 
of action of the compound and its biological target are still undisclosed and are 
currently under active investigation. 
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4.3 Conclusion 
A study towards the total synthesis of rakicidin A was conducted, leading to the 
optimization of reaction conditions for the several steps leading to crucial 
intermediates. Different strategies were undertaken to obtain a number of 
stereochemical configurations apt to the obtainment of natural rakA and other 
synthetic isomers. The project focused on the obtainment of three crucial 
building blocks such as the fatty acid side chain (carrying a challenging triad of 
stereogenic centers), the β-HOAsn fragment and the precursor to the APD 
fragment. Specific attention was put on the asymmetric methods allowing for the 
construction of the 5 stereocenters of the molecule in a reproducible and 
reliable way. After a full total synthesis had been completed, rakA was 
confirmed as a correct reproduction of the natural compound and further studies 
are being conducted to disclose its activity on a biomolecular level. 
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4.4 Experimental section 
4.4.1 General methods 
All reactions with air and moisture sensitive compounds were conducted in 
flame-dried glassware under an atmosphere of argon. Dichloromethane, MeCN, 
THF and toluene were dried over aluminum oxide via an MBraun SPS-800 
solvent purification system. Benzene and Et2O were dried over activated 
molecular sieves (4 Å). DMF, DME and MeOH were purchased as dried. If not 
otherwise stated reagents were used as received from commercial suppliers. 
TLC analysis was carried out on silica coated aluminum foil plates (Merck 
Kieselgel 60 F254). The TLC plates were visualized by UV irradiation and/or by  
staining with either CAM stain or KMnO4 stain. Flash column chromatography 
(FCC) was carried out using silica gel (230-400 mesh particle size, 60 Å pore 
size) as stationary phase. Optical rotation was measured on an ADP 440+ 
spectrometer. Mass spectra (HRMS) were recorded on a Bruker Daltonics 
MicrOTOF time-of-flight spectrometer with positive electrospray ionization, or 
negative ionization when stated. Nuclear magnetic resonance (NMR) spectra 
were recorded on a Varian Mercury 400 MHz spectrometer or a Bruker BioSpin 
GmbH 400 MHz spectrometer, running at 400 and 100 MHz for 1H and 13C, 
respectively. 1H and 13C NMR spectra of Rakicidin A were recorded on a Bruker 
950 MHz spectrometer. Chemical shifts (δ) are reported in ppm relative to the 
residual solvent signals. Multiplicities are indicated using the following 
abbreviations: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = 
broad. LC-MS and HPLC analysis and purification were performed using a 
Gilson HPLC system and a PerkinElmer Flexar SQ 300 MS detector. 
 
4.4.2 Synthetic procedures 
Diethyl (2R,3S)-2-azido-3-hydroxysuccinate 39 
To a stirred solution of (-)-diethyl D-tartrate (2.3 g, 11.2 mmol, 1.0 
eq.) in 12 mL CCl4 was added SOCl2 (4.0 g, 33.6 mmol, 3.0 eq.). The 
reaction was heated to reflux and stirred for 6 h. The mixture was cooled to 
room temperature and concentrated to dryness under reduced pressure. The 
residue was dissolved in DMF and sodium azide (1.46 g, 22.4 mmol, 2.0 eq.) 
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was added to the solution. The reaction was stirred at room temperature for 4 h 
and quenched with water. The mixture was extracted with ethyl acetate and the 
combined organic layer was washed with brine and then dried with Na2SO4. The 
solution was concentrated under reduced pressure and the residue was purified 
by column chromatography (33%EtOAc/67% Hexane) to give 39 as a colorless 
oil (yield 65%). αD25.6 = -6.8 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 4.63 
(dd, J = 5.5, 2.7 Hz, 1H), 4.33 – 4.20 (m, 4H), 3.34 (d, J = 5.5 Hz, 1H), 1.30 (t, J 
= 2.9 Hz, 6H). 13C NMR (100 MHz, CDCl3) 170.87, 167.06, 76.82, 72.16, 64.52, 
62.83, 62.48, 14.15. HRMS (ESI): Calc. C8H14N3O5+: 232.0928; found: 
232.0930 [M + H]+. 
 
Diethyl (2R,3S)-2-amino-3-hydroxysuccinate 40 
To a stirred solution of azide 39 (342 mg, 1.48 mmol) in ethyl acetate 
was added palladium in carbon (10%, 30 mg). The reaction 
atmosphere was evacuated and replaced by H2 three times, and then stirred 
vigorously under 1 atm hydrogen gas for 2 h. The mixture was concentrated 
under reduced pressure and the residue was purified by column 
chromatography (10% MeOH/90% CH2Cl2) to give 40 (yield 60%) as a colorless 
oil. αD26.9 = 16.8 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 4.48 (d, J = 3.1 
Hz, 1H), 4.30 – 4.11 (m, 4H), 3.89 (d, J = 3.1 Hz, 1H), 2.53 – 2.17 (br s, 2H), 
1.26 (q, J = 7.2 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 172.11, 171.90, 72.92, 
62.05, 61.54, 57.65, 14.20, 14.18. HRMS (ESI): Calc. C8H16NO5+: 206.1023; 
found: 206.1027 [M + H]+. 
 
(2R,3S)-Erythro-β-hydroxyaspartic acid 41 
A stirred solution of 40 (300 mg, 1.46 mmol, 1.0 eq.) in ethanol was 
cooled to 0°C with an ice bath and LiOH·H2O (245 mg, 5.84 mmol, 4.0 eq.) was 
added. The bath was removed and mixture was stirred at RT for 2h. The pH 
was adjusted to neutral and the compound was extracted 3 times with EtOAc. 
The solvent was concentrated under reduced pressure and the product was 
used without further purification (quant.). 1H NMR (400 MHz, dmso-d6) δ 3.86 
(s, 1H), 3.41 (s, 1H). HRMS (ESI): Calc. C4H6NO5-: 148.0251; found: 148.0248 
[M - H]-. 
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(R)-4-Benzyl-3-(14-methylpentadecanoyl)oxazolidin-2-one 43 
A stirring solution of 14-methylpentadecanoic acid (670 mg, 2.61 
mmol, 1 equiv.) in anhydrous THF (26 mL) was cooled to 0°C 
under Ar and NEt3 (1.09 mL, 7.84 mmol, 3 equiv.) was added. After 5 minutes 
PivCl (0.35 mL, 2.87 mmol, 1.1 equiv.) was added dropwise. The mixture was 
stirred for 20 minutes at 0°C and for 30 minutes at ambient temperature (TLC 
analysis). Then, DMAP (95.8 mg, 0.784 mmol, 0.3 equiv.) was added followed 
by (R)-4-benzyl-2-oxazolidinone (556 mg, 3.14 mmol, 1.2 equiv.) and the 
mixture was stirred at 50°C for 5 hours. The reaction was quenched at ambient 
temperature with brine and extracted with ether (3 x 20 mL). The organic phase 
was dried (Na2SO4), filtered, concentrated and the crude product was purified 
by FCC (pentane/EtOAc 95:5 to 90:10) to furnish 43 (782 mg, 72%) as a white 
solid. αD28 = -62 (c 1.0, EtOH). 1H NMR (400 MHz, CDCl3) δ 7.36-7.19 (m, 5H), 
4.71-4.62 (m, 1H), 4.22-4.13 (m, 2H), 3.29 (dd, J = 13.4 and 3.3 Hz, 1H), 3.02-
2.83 (m, 2H), 2.76 (dd, J = 13.4 and 9.6 Hz, 1H), 1.74-1.63 (m, 2H), 1.51 (n, J = 
6.6 Hz, 1H), 1.42-1.11 (m, 20H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (100 MHz, 
CDCl3) δ 173.6, 153.6, 135.5, 129.6, 129.1, 127.5, 66.3, 55.3, 39.2, 38.1, 35.7, 
30.1, 29.9, 29.8, 29.6, 29.3, 28.1, 27.6, 24.4, 22.8. HRMS (ESI): Calc. 
C26H41O3NNa+: 438.2979; found: 438.2982 [M + Na]+. 
 
(R)-4-Benzyl-3-((R)-2,14-dimethylpentadecanoyl)oxazolidin-2-
one 44 
(R)-4-Benzyl-3-(14-methylpentadecanoyl)oxazolidin-2-one 43 
(6.54 g, 15.7 mmol, 1 equiv.) was dissolved in anhydrous THF (95 mL) and 
cooled to -78 °C, before NaHMDS (1.0 M in THF, 1.2 equiv., 18.9 mL, 18.9 
mmol) was added slowly. The reaction mixture was then stirred at -78 °C for 1 
hour before MeI (5 equiv., 4.9 mL, 78.5 mmol) was added slowly. The reaction 
mixture was stirred for 3 hours at -78 °C, before it was quenched with sat. 
NH4Cl (8 mL). The aqueous phase was extracted with CH2Cl2 and the organic 
phase was then washed with KHSO4 (5%, aq.), sat. Na2S2O3 (aq.) and brine, 
before it was dried (Na2SO4), filtered and concentrated. The crude product was 
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purified by dry column vacuum chromatography (0-15% EtOAc in pentane, 1% 
increments) to furnish 44 (5.10 g, 76%) as a colourless oil. αD28 = -69.1 (c 1.0, 
CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.36-7.19 (m, 5H), 4.67 (ddt, J = 10.1, 6.7 
and 3.2 Hz, 1H), 4.23-4.13 (m, 2H), 3.70 (h, J = 6.8 Hz, 1H), 3.26 (dd, J = 13.3 
and 3.3 Hz, 1H), 2.76 (dd, J = 13.3 and 9.6 Hz, 1H), 1.78-1.67 (m, 1H), 1.56-
1.46 (m, 1H), 1.44-1.35 (m, 1H), 1.32-1.18 (m, 18H), 1.22 (d, J = 6.9 Hz, 3H), 
1.18-1.10 (m, 2H), 0.86 (dd, J = 6.6 and 0.7 Hz, 6H). 13C NMR (100 MHz, 
CDCl3) δ 177.4, 153.1, 135.4, 129.5, 129.0, 127.4, 66.1, 55.4, 39.1, 38.0, 37.8, 
33.5, 30.0, 29.8, 29.7, 29.6, 28.1, 27.5, 27.4, 22.8, 17.5. HRMS (ESI): Calc. 
C27H44O3N+: 430.3316; found: 430.3319 [M + H]+. 
 
(R)-2,14-Dimethylpentadecan-1-ol 45 
(R)-4-Benzyl-3-((R)-2,14-dimethylpentadecanoyl)oxazolidin-2-one 
44 (1.03 g, 2.39 mmol, 1 equiv.) was dissolved in anhydrous THF (60 mL) and 
cooled to 0°C, before anhydrous MeOH (0.15 mL) and LiBH4 (2.0 M in THF, 2.0 
equiv., 2.4 mL, 4.8 mmol) were added. The reaction mixture was then stirred at 
0°C for 2 hours and an additional 5 hours at ambient temperature. The reaction 
mixture was quenched by slow addition of NaOH 2N (10 mL) and stirred until 
the solution was clear (5-10 minutes). The solution was extracted with Et2O (3 x 
50 mL) and the combined organic phases were washed with H2O and brine, 
dried (Na2SO4), filtered and concentrated. The crude product was purified by 
flash column chromatography (pentane/Et2O 9:1) to afford alcohol 45 (0.57 g, 
93%) as a colourless liquid. αD28 = +7.2 (c 1.0, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ 3.50 (dd, J = 10.5 and 5.7 Hz, 1H), 3.41 (dd, J = 10.5 and 6.6 Hz, 1H), 
1.66-1.55 (m, 1H), 1.50 (m, 1H), 1.43-1.06 (m, 22H), 0.91 (d, J = 6.7 Hz, 3H), 
0.86 (d, J = 6.6 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 68.6, 39.2, 35.9, 33.3, 
30.1, 29.9, 29.8, 28.1, 27.6, 27.1, 22.8, 16.7. 
 
(R)-2,14-Dimethylpentadecanal 46 
The alcohol 45 (7.8 mmol, 2.0 g, 1 equiv.) was azeotroped with 
anhydrous benzene and then dissolved in CH2Cl2/DMSO (2:1, 106 mL) and 
cooled to 0°C. Triethylamine (5 equiv., 39 mmol, 5.4 mL) and SO3·pyridine (4 
equiv., 31.2 mmol, 4.97 g) were added sequentially and the reaction mixture 
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was stirred for 60 minutes at 0°C before it was quenched with brine. The layers 
were separated and the aqueous phase was extracted with CH2Cl2 (3 x 20 mL). 
The organic phase was dried (Na2SO4), filtered and concentrated. The crude 
product was purified by flash column chromatography (pentane/CH2Cl2 6:1) to 
give the desired aldehyde 46 (1.9 g, 96%) as a colourless liquid. αD28 = -19.7 (c 
1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 9.61 (d, J = 2.0 Hz, 1H), 2.37-2.27 
(m, 1H), 1.75-1.64 (m, 1H), 1.50 (m, 1H), 1.32-1.12 (m, 21H), 1.08 (d, J = 7.0 
Hz, 3H), 0.85 (d, J = 6.6 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 205.6, 46.5, 
39.2, 30.7, 30.1, 29.9, 29.8, 29.7, 29.6, 28.1, 27.6, 27.1, 22.8, 13.5 HRMS 
(ESI): Calc. C17H34ONa+: 277.2507; found 277.2502 [M + Na]+. 
 
Ethyl (R,E)-4,16-dimethylheptadec-2-enoate 47 
Ethyl (triphenylphosphoranylidene)acetate (8.96 
g, 25.73 mmol, 4.8 equiv.) was dissolved in 16 mL dry CH2Cl2. Aldehyde 46 
(1.74 g, 5.36 mmol, 1 equiv.) was dissolved in 9 mL dry CH2Cl2 and added to 
the solution containing the Wittig reagent. The mixture was stirred for 3 hours at 
room temperature. The reaction was then diluted with H2O after completion and 
extracted with CH2Cl2 three times. The extract was dried with Na2SO4 and 
concentrated in vacuum. The crude residue was purified by FCC (yield 95%) 
(AcOEt/pentane 1:99). 1H NMR (400 MHz, CDCl3) δ 6.86 (dd, J = 15.7, 7.9 Hz, 
1H), 5.76 (d, J = 15.7 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 2.28 (dt, J = 13.7, 6.8 
Hz, 1H), 1.57 – 1.45 (m, 2H), 1.30 – 1.24 (m, 21H), 1.14 (t, J = 7.1 Hz, 3H), 1.03 
(d, J = 6.7 Hz, 3H), 0.86 (d, J = 6.6 Hz, 6H). HRMS (ESI): Calc. C21H40O2Na+: 
347.2921; found 347.2917 [M + Na]+. 
 
(R,E)-4,16-dimethylheptadec-2-en-1-ol 48 
To a solution of ethyl (R,E)-4,16-
dimethylheptadec-2-enoate 47 (904 mg, 3.2 mmol, 1.0 equiv.) in dry CH2Cl2 (10 
mL) was added diisobutylaluminum hydride (9.6 mL of a 1.0 M solution in 
hexane, 9.6 mmol, 3.0 equiv.) at 0 °C. After stirring for 2 hours at room 
temperature, the reaction was quenched with methanol. After an aqueous 
Rochelle Salt solution and diethyl ether were added, the mixture was warmed to 
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room temperature and stirred vigorously until the resulting white slurry was 
completely dissolved. After the phases were separated, the aqueous layer was 
extracted with diethyl ether. The combined organic extracts were washed with 
water and brine, dried over Na2SO4, and concentrated in vacuum. The residue 
was purified by FCC on silica gel (pentane/EtOAc = 8/1) to give 48 as a 
colorless oil (yield 96%) 1H NMR (400 MHz, CDCl3) δ 5.56-5.59 (m, 2H), 4.09 
(d, J = 3.2 Hz, 2H), 2.37-2.27 (m, 1H), 1.75-1.64 (m, 1H), 1.50 (m, 1H), 1.32-
1.12 (m, 21H), 1.08 (d, J = 7.0 Hz, 3H), 0.85 (d, J = 6.6 Hz, 6H). HRMS (ESI): 
Calc. : C19H38ONa+: 305.2815; found 305.2811 [M + Na]+. 
 
((2R,3R)-3-((R)-14-methylpentadecan-2-yl)oxiran-
2-yl)methanol 49 
tert-Butyl hydroperoxide (4 M in decane, 0.138 mL, 2.0 equiv.) was diluted with 
dry CH2Cl2 (0.75 mL) and dried over microwave activated 4 Å ground molecular 
sieves. A Schlenk flask was charged with titanium tetraisopropoxide (4 μL, 
0.0138 mmol, 0.05 equiv.) and dry CH2Cl2 (2 mL) and dried over microwave 
activated 4 Å ground molecular sieves. (R,E)-4,16-dimethylheptadec-2-en-1-ol 
48 (82 mg, 0.275 mmol, 1.00 equiv.) was dissolved in dry CH2Cl2 (1 mL) and 
dried over microwave activated 4 Å ground molecular sieves. The titanium 
tetraisopropoxide was cooled to -20°C and stirred for another 30 min. Then D-(-
)-diethyltartrate (3.4 mg, 0.0165 mmol, 0.06 equiv.) was added. After 30 min the 
solution of the allyl alcohol was added slowly. Directly afterwards the tert-butyl 
hydroperoxide solution was added and the reaction mixture stirred overnight at -
20°C. The reaction mixture was quenched at -20°C. by addition of a solution 
containing iron(II)sulfate heptahydrate (3.3 g), citric acid (1.1 g), and water (10 
mL). The mixture was stirred vigorously and allowed to warm to room 
temperature for 30 min, followed by extraction with diethyl ether and drying over 
Na2SO4. Purification by FCC (pentane/diethyl ether) to obtain 49 as colorless 
oil. (Yield 86%, dr 9:1 determined by 1H-NMR). 1H NMR (400 MHz, CDCl3) δ 
3.92 (dd, J = 12.5, 2.4 Hz, 1H), 3.62 (dd, J = 12.5, 4.3 Hz, 1H), 2.93 (dt, J = 4.3, 
2.4 Hz, 1H), 2.77 (dd, J = 7.3, 2.4 Hz, 1H), 1.70-1.60 (m, 1H), 1.51 (dt, J = 13.3, 
6.6 Hz, 2H), 1.26 (m, 21H), 0.92 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 6.6 Hz, 6H). 
HRMS (ESI): Calc. : C19H38O2Na+: 321.2764; found 321.2760 [M + Na]+. 
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(2S,3R,4R)-2,4,16-trimethylheptadecane-1,3-diol 
50 
Copper(I)cyanide (223 mg, 2.49 mmol, 3.00 equiv.) was suspended in dry THF 
(10 mL) and cooled to -70°C. A solution of methyl lithium (1.6 M in diethyl ether, 
5 mL, 6 equiv.) was slowly added. The solution was stirred for 20 min at -70°C. 
Then ((2R,3R)-3-((R)-14-methylpentadecan-2-yl)oxiran-2-yl)methanol 49 (261 
mg, 0.829 mmol, 1.00 equiv.) dissolved in dry THF (5 mL) was added slowly. 
The solution was stirred for 1 h at -70°C, then it was warmed to -20°C and 
stirred at that temperature overnight. The reaction was allowed to reach 0°C., 
quenched with saturated ammonium chloride solution, and stirred vigorously for 
10 min. Then aqueous ammonia solution (about 25%, 5mL) was added and the 
mixture was stirred until the aqueous phase turned into a light. The phases 
were separated and the aqueous phase was extracted with ethyl acetate. The 
combined organic phases were dried over Na2SO4 and concentrated in vacuum. 
Purification by FCC (pentane/diethyl ether 1:1) to obtain the title compound as a 
colorless oil (yield 82%). 1H NMR (400 MHz, CDCl3) δ 3.77 (d, J = 10.4 Hz, 1H), 
3.70 – 3.59 (dd, J= 10.5, 8.3 Hz, 1H), 2.75 – 2.70 (br s, 1H), 2.25 – 2.20 (br s, 
1H), 1.97 – 1.79 (m, 1H), 1.70 – 1.60 (m, 1H), 1.55 – 1.45 (m, 2H), 1.35 – 1.21 
(m, 21H), 0.95 (d, J = 6.9 Hz, 3H), 0.89 (d, J = 7.0 Hz, 3H), 0.86 (d, J = 6.6 Hz, 
6H). HRMS (ESI): Calc. : C20H42O2Na+: 337.3077; found 337.3074 [M + Na]+. 
 
(2R,3R,4R)-3-hydroxy-2,4,16-
trimethylheptadecanoic acid 52 
PhI(OAc)2 (483 mg, 1.5 mmol, 1.5 equiv.) and TEMPO (31 mg, 0.2 mmol, 0.2 
equiv.) were added sequentially to a stirred solution of the diol 50 (329 mg, 1.0 
mmol, 1 equiv.) in CH2Cl2 (6 mL) at room temperature. After completion, the 
mixture was treated with sat. Na2S2O3. The separated organic phase was 
washed with sat. NaHCO3 solution and brine, dried over Na2SO4 and 
concentrated in vacuum. The crude aldehyde was used in next step without 
purification. The aldehyde (260 mg, 0.83 mmol, 1 equiv.) was dissolved in t-
BuOH (5.4 mL) and 2-Me-2-butene (10 equiv., 8.32 mmol, 0.88 mL) was added 
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followed by H2O (1.4 mL). The mixture was then cooled to 0°C and NaClO2 (4 
equiv., 3.33 mmol, 301 mg) was added followed by NaH2PO4 (5 equiv., 4.16 
mmol, 499 mg). The mixture was left stirring at 0°C for 17 hours. After 
completion, Et2O (30 mL) was added followed by citric acid 0.5 M (15 mL). The 
layers were separated and the aqueous phase was back-extracted with Et2O (2 
x 10 mL). The combined organic phases were dried over Na2SO4 and 
concentrated in vacuum. The crude product was purified by FCC 
(pentane/EtOAc 9:1 then CH2Cl2/MeOH/AcOH 90:10:0.1) and obtained as a 
colorless oil. (yield 73% over 2 steps) 1H NMR (400 MHz, CDCl3) δ 3.60-3.50 
(br s, 1H), 2.79-2.56 (br s, 1H), 1.67-1.47 (m, 2H), 1.45-1.07 (m, 25H), 0.93-
0.80 (m, 9H). 13C NMR (100 MHz, CDCl3) δ 181.7, 76.0, 39.2, 34.9, 34.1, 33.3, 
30.1, 30.0, 29.9, 29.8, 28.1, 27.6, 27.4, 22.8, 14.4, 12.7. HRMS (ESI): Calc. : 
C20H39O3-: 327.2905; found 327.2915 [M – H]-. 
 
Benzyl (2R,3R,4R)-3-hydroxy-2,4,16-
trimethylheptadecanoate 53 
The β-hydroxy acid 52 (0.83 mmol, 1 equiv.) was dissolved in anhydrous 
DMF/CH2Cl2 (2:1, 9.4 mL) and K2CO3 (3.0 equiv., 2.49 mmol, 344 mg) was 
added followed by BnBr (2.5 equiv., 2.08 mmol, 247 μL). The reaction was 
stirred for 48 hours at ambient temperature and poured into H2O (15 mL). The 
aqueous phase was extracted with Et2O (30 mL) and the organic phase was 
washed with HCl 1 M (10 mL) and brine (10 mL), dried (Na2SO4), filtered and 
concentrated. The crude product was purified by flash column chromatography 
(pentane/Et2O 10:1) to afford the desired benzyl ester 53 (yield 82%) as a 
colourless oil. 1H NMR (400 MHz, CDCl3) δ 7.40-7.30 (m, 5H), 5.15 (s, 2H), 
3.45-3.35 (m, 1H), 2.81 – 2.71 (br s, 1H), 2.53 (d, J = 7.7 Hz, 1H), 1.60-1.47 (m, 
2H), 1.44-1.10 (m, 25H), 0.86 (d, J = 6.6 Hz, 9H).13C NMR (100 MHz, CDCl3) δ 
176.5, 135.9, 128.7, 128.4, 128.3, 76.2, 66.5, 43.3, 39.2, 35.2, 34.1, 30.1, 30.0, 
29.9, 29.8, 28.1, 27.6, 27.4, 22.8, 14.6, 13.0. HRMS (ESI): Calc. C27H46O3+: 
419.3520; found: 419.3528 [M + H]+. 
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(R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-2-((S)-2,2-
dimethyl-5-oxo-1,3-dioxolan-4-yl)acetic acid 56 
To a stirring solution of (R,S)-HOAsp 41 (460 mg, 3.09 mmol) in 
dioxane (9 mL) was added 10% Na2CO3 (aq., 8.1 mL) followed by a solution of 
FmocOSu (1.2 g, 3.55 mmol) in dioxane (9 mL) dropwise. The mixture was left 
stirring for 24 hours at ambient temperature. After completion, H2O (20 mL) was 
added and the aqueous phase was washed with Et2O (10 mL). The organic 
phase was extracted with sat. NaHCO3 (10 mL) and the combined aqueous 
layers were then acidified to pH 1 with HCl 1 N. The aqueous phase was 
extracted with EtOAc (3 x 20 mL) and the combined organic phases were dried 
(Na2SO4), filtered and concentrated under reduced pressure. The remaining oil 
was precipitated from CH2Cl2/pentane and concentrated again to give the N-
protected HOAsp (1.11 g, quantitative) as a white solid, which was of high 
enough purity to be advanced to the next reaction without further purification. 
αD24 = -7 (c 1.0, CHCl3). 1H NMR (400 MHz, DMSO-d6) δ 7.90 (d, J = 7.5 Hz, 
2H), 7.72 (t, J = 7.4 Hz, 2H), 7.42 (t, J = 7.5 Hz, 2H), 7.33 (q, J = 6.8 Hz, 2H), 
7.24 (d, J = 9.7 Hz, 1H), 5.93 (d, J = 8.2 Hz, 1H), 4.72 (d, J = 6.6 Hz, 1H), 4.38 
(s, 1H), 4.28 – 4.13 (m, 3H). 
To a stirring solution of the above N-Fmoc-HOAsp (200 mg, 0.53 mmol) in 2,2-
dimethoxypropane (5.42 mL, 42.4 mmol) was added DMF (0.77 mL) and 
pTSA·H2O (30 mg, 0.15 mmol). The mixture was stirred at 40°C for 24 hours. 
The solvents were evaporated under reduced pressure and the residue was re-
dissolved in EtOAc (20 mL) and washed with H2O (10 mL) and brine (10 mL). 
The combined organic phases were dried (Na2SO4), filtered and concentrated 
under reduced pressure. The crude compound was purified by flash column 
chromatography (EtOAc/MeOH 9:1) to furnish the ketal-protected product 56 as 
a colourless oil. The compound was precipitated from EtOAc/pentane and 
filtered to give a powdered white solid (178 mg, 82% over two steps). αD23 = -
14.4 (c 1.0, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 7.4 Hz, 2H), 7.67 
– 7.53 (m, 2H), 7.41 (t, J = 7.3 Hz, 2H), 7.32 (t, J = 7.3 Hz, 2H), 5.54 (d, J = 8.2 
Hz, 1H), 5.07 (d, J = 7.0 Hz, 1H), 4.86 (s, 1H), 4.63 – 4.51 (m, 1H), 4.46 (d, J = 
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6.0 Hz, 2H), 1.55 (d, J = 5.1 Hz, 6H). HRMS (ESI): Calc. C22H20NO7-: 410.1245; 
found: 410.1240 [M - H]-. 
 
Benzyl (2R,3R,4R)-3-((R)-2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-2-((S)-2,2-dimethyl-5-oxo-1,3-
dioxolan-4-yl)acetoxy)-2,4,16-trimethylheptadecanoate 57 
The starting alcohol 53 (270 mg, 0.645 mmol, 1 equiv.) was dissolved in a 
mixture of anhydrous CH2Cl2/DMF (9:1, 6.5 mL) and acid 56 (2.5 equiv., 1.63 
mmol, 669 mg) was added under an Ar atmosphere. The mixture was cooled to 
0°C and DCC (3 equiv., 1.95 mmol, 402 mg) and DMAP (0.3 equiv., 0.188 
mmol, 23 mg) were added sequentially. The reaction was stirred at 0°C for 5 
hours before it was diluted with ether (25 mL). The generated white solid (DCU) 
was filtered off, and the mixture was poured into a separating funnel containing 
H2O and ether. The layers were separated and the aqueous phase was 
backextracted with ether (2 x 45 mL). The combined organic phases were 
washed with brine (90 mL), dried (Na2SO4), filtered, and concentrated. The 
crude was purified by flash column chromatography (pentane/Et2O 9:1 to 1:1) 
to afford the desired product 57 (327 mg, 63%) as a colourless oil. 1H NMR 
(400 MHz, CDCl3) δ 7.76 (d, J = 7.6 Hz, 2H), 7.58 (dd, J = 7.5 and 4.0 Hz, 2H), 
7.42-7.29 (m, 9H), 5.46 (d, J = 10.1 Hz, 1H), 5.26-5.14 (m, 3H), 5.05-4.92 (m, 
2H), 4.38-4.30 (m, 2H), 4.20 (t, J = 7.2 Hz, 1H), 2.82 (p, J = 7.1 Hz, 1H), 1.84-
1.74 (m, 1H), 1.65 (s, 3H), 1.57-1.47 (m, 4H), 1.41-1.06 (m, 25H), 0.88-0.86 (m, 
9H). 13C NMR (100 MHz, CDCl3) δ 173.2, 169.6, 168.4, 155.9, 143.9, 143.7, 
141.4, 135.7, 128.8, 128.6, 128.4, 127.9, 127.2, 125.2, 120.1, 111.4, 80.5, 74.9, 
67.8, 66.7, 53.7, 47.1, 42.0, 39.2, 34.5, 33.4, 30.1, 29.9, 29.8, 29.7, 28.1, 27.6, 
27.1, 26.8, 26.0, 22.8, 14.2, 14.0. HRMS (ESI): C49H69N2O9+: 829.4998, found: 
829.4985 [M + NH4]+. 
 
Methyl N-(2-bromoacetyl)-N-methylglycinate 59 
Sarcosine methyl ester hydrochloride (2.00 g, 14.3 mmol, 1 
equiv.) was dissolved in anhydrous CH2Cl2 (85 mL) under argon. Anhydrous 
triethylamine (43.0 mmol, 6.0 mL, 3.0 equiv.) was added, and the mixture was 
cooled to -78 °C. A solution of bromoacetyl bromide (1.9 mL. 21.5 mmol, 1.5 
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equiv.) in anhydrous CH2Cl2 (85 mL) was added dropwise over 5 minutes via an 
addition funnel. The reaction was stirred at -78°C for 30 min and was then 
allowed to warm to -12°C over 1.5 hours. The reaction mixture was washed with 
1 M HCl (aq., 100 mL) and brine (100 mL). The water phases were back-
extracted with CH2Cl2 (3 x 50 mL) and the combined organic phases were dried 
(Na2SO4), filtered and concentrated in vacuo to give a brown oil that was further 
purified by flash column chromatography (pentane/EtOAc 6:4) to furnish the 
product as a clear oil (yield 93%). 1H NMR (400 MHz, CDCl3) δ 4.02 (s, 2H), 
3.83 (s, 2H), 3.63 (s, 3H), 3.07 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 169.1, 
167.2, 52.1, 49.6, 37.2, 26.0. HRMS calc.: C6H10BrNO3Na+: 245.9742; found: 
245.9738 [M + Na]+. 
 
Methyl N-(2-(diethoxyphosphoryl)acetyl)-N-methylglycinate 60 
Methyl N-(2-bromoacetyl)-N-methylglycinate 59 (2.70 g, 12.1 
mmol, 1 equiv.) was dissolved in anhydrous 1,2-dichloroethane (12.8 mL) under 
argon while stirred. P(OEt)3 (3.1 mL, 18.1 mmol, 1.5 equiv.) was added in one 
portion and the reaction was heated to reflux. After 22 hours the reaction was 
allowed to cool to ambient temperature and concentrated in vacuo. Flash 
column chromatography (EtOAc/MeOH 98:2 to 90:10) furnished the desired 
phosphonate (yield 93%) as a clear yellow oil. 1H NMR (400 MHz, CDCl3) δ 
4.22-4.08 (m, 6H), 3.73 (s, 3H), 3.19 (s, 3H), 3.11 (d, J = 22.2 Hz, 1H), 1.34 (t, J 
= 7.0, Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 169.3, 165.6, 62.7, 52.35, 49.6, 
37.8, 33.8, 16.3. HRMS calc.: C10H20NPO5Na+: 304.0926; found: 304.0926 [M + 
Na]+. 
 
Lithium N-(2-(diethoxyphosphoryl)acetyl)-N-methylglycinate 61 
The methyl ester 60 (1.34 g, 4.76 mmol, 1 equiv.) was dissolved 
in THF/H2O (1:1, 48 mL) and cooled to 0°C while stirred. LiOH·H2O (0.21 g, 5.0 
mmol, 1.05 equiv.) was added in one portion. After 2.5 hours the reaction was 
concentrated in vacuo to yield the desired lithium salt (quantitative) as a white 
solid. 1H NMR (400 MHz, D2O) δ 4.23-4.09 (m, 4H), 4.01 (3.91) (s, 2H), 3.11 
(2.92) (s, 3H), 1.31 (td, J = 7.1 and 3.6 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 
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175.8 (175.4), 167.2 (166.8), 64.1, 54.7 (52.0), 37.7 (35.2), 15.5. HRMS calc.: 
C9H18NPO5Na+: 290.0769; found: 290.0764 [M + Na]+. 
 
Allyl N-(2-(diethoxyphosphoryl)acetyl)-N-methylglycinate 62 
In a flame dried flask equipped with a magnetic stirring bar, 
salt 61 (26 mg, 0.093 mmol, 1 equiv.) was dissolved in anhydrous CH2Cl2 (1 
mL), a solution of HCl in dioxane (4 N, 1.2 equiv., 0.112 mmol, 28 μL) was 
added and the mixture was stirred under Ar for 20 minutes. The volatiles were 
evaporated under reduced pressure and the residue was re-dissolved in DMSO 
(1 mL). K2CO3 (51 mg, 0.372 mmol., 4 equiv.) and allyl bromide (24 μL, 0.279 
mmol, 3 equiv.) were added. The mixture was stirred at rt for 12 h and then 
partitioned between EtOAc and brine. The organic phase was separated and 
the aqueous phase was extracted with EtOAc. The combined organic phase 
was dried over Na2SO4 and concentrated. Flash chromatography (petroleum 
ether/EtOAc, 15/1) gave 62 (yield 90%) as a colorless oil. 1H NMR (400 MHz, 
CDCl3) δ 6.04 – 5.75 (m, 1H), 5.40 – 5.15 (m, 2H), 4.63 (dt, J = 5.8, 1.3 Hz, 2H), 
4.20-4.10 (m, 4H), 3.22 (s, 3H), 3.11 (s, 2H), 1.31 (td, J = 7.1 and 3.6 Hz, 6H). 
HRMS calc.: C12H22NO6PNa+: 330.1077; found: 330.1073 [M + Na]+. 
 
(2S,3S,4R)-3-Hydroxy-2,4,16-trimethylheptadecanal 
65 
Chiral aldehyde 46 (670 mg, 2.63 mmol, 1 equiv.) was dissolved in anhydrous 
DMF (1.5 mL) under an Ar atmosphere, cooled to 4°C, and L-proline (0.2 equiv., 
0.53 mmol, 61 mg) was added. Then a solution of propanal (2 equiv., 5.27 
mmol, 0.38 mL) in anhydrous DMF (1.5 mL) was added over a period of 40 
hours using a syringe pump. After the end of the addition the mixture was 
stirred at the same temperature for an additional 24 hours. The reaction was 
quenched with water (10 mL) and extracted with ether (3 x 20 mL). The organic 
phase was dried (Na2SO4), filtered and concentrated. The crude product was 
purified by flash column chromatography (pentane/Et2O 10:1) to furnish the 
desired anti-product 65 (yield 33%) as a colourless liquid, along with syn-
product (3%) and starting aldehyde (57%). The diastereoselectivity of the 
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reaction was calculated as anti:syn 10:1, based on the weight of the 
diastereoisomers and 1H NMR analysis. 1H NMR (400 MHz, CDCl3) δ 9.78 (d, 
J = 1.8 Hz, 1H), 3.77-3.69 (m, 1H), 2.54 (p, J = 7.7 Hz, 1H), 2.11 (d, J = 4.8 Hz, 
1H), 1.66-1.47 (m, 2H), 1.44-1.11 (m, 22H), 1.08 (d, J = 7.3 Hz, 3H), 0.91-0.81 
(m, 9H). 
 
Benzyl (2S,3S,4R)-3-hydroxy-2,4,16-
trimethylheptadecanoate 66 
Aldehyde 66 was oxidized to the corresponding carboxylic acid according to the 
procedure used for 52. The acid was benzylated according to the procedure 
used for 53. (yield 68% for two steps) colourless oil. αD27 = +9.4 (c 1.0, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.40-7.30 (m, 5H), 5.16 (s, 2H), 3.63-3.59 (m, 1H), 
2.69 (p, J = 7.3 Hz, 1H), 2.40 (d, J = 6.4 Hz, 1H), 1.60-1.47 (m, 2H), 1.44-1.10 
(m, 25H), 0.86 (d, J = 6.6 Hz, 9H).13C NMR (100 MHz, CDCl3) δ 176.5, 135.9, 
128.7, 128.4, 128.3, 76.2, 66.5, 43.3, 39.2, 35.2, 34.1, 30.1, 30.0, 29.9, 29.8, 
28.1, 27.6, 27.4, 22.8, 14.6, 13.0. HRMS (ESI): Calc. C27H47O3+: 419.3520; 
found: 419.3528 [M + H]+. 
 
Benzyl (2S,3S,4R)-3-((S)-2-((((9H-fluoren-9-
yl)methoxy)carbonyl)amino)-2-((S)-2,2-dimethyl-5-oxo-1,3-
dioxolan-4-yl)acetoxy)-2,4,16-rimethylheptadecanoate 67 
67 was obtained with the same procedure used for 57.  
αD26 = -4.1 (c 1.0, CH2Cl2). 1H NMR (400 MHz, CDCl3) δ 7.76 
(d, J = 7.6 Hz, 2H), 7.58 (dd, J = 7.5 and 4.0 Hz, 2H), 7.42-7.29 (m, 9H), 5.42 
(d, J = 10.1 Hz, 1H), 5.16-5.04 (m, 3H), 5.01-4.88 (m, 2H), 4.42-4.34 (m, 2H), 
4.26 (t, J = 7.2 Hz, 1H), 2.92 (p, J = 7.1 Hz, 1H), 1.84-1.74 (m, 1H), 1.65 (s, 
3H), 1.57-1.47 (m, 4H), 1.41-1.06 (m, 25H), 0.88-0.86 (m, 9H). 13C NMR (100 
MHz, CDCl3) δ 173.2, 169.6, 168.4, 155.9, 143.9, 143.7, 141.4, 135.7, 128.8, 
128.6, 128.4, 127.9, 127.2, 125.2, 120.1, 111.4, 80.5, 74.9, 67.8, 66.7, 53.7, 
47.1, 42.0, 39.2, 34.5, 33.4, 30.1, 29.9, 29.8, 29.7, 28.1, 27.6, 27.1, 26.8, 26.0, 
22.8, 14.2, 14.0. HRMS (ESI): C49H69N2O9+: 829.4998, found: 829.4985 [M + 
NH4]+. 
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